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Resumo  
Nos últimos anos a biotecnologia marinha tem revelado um papel crucial no futuro da 
bioindústria. Entre os muitos recursos marinhos, as cianobactérias têm revelado um grande 
potencial na produção de compostos bioativos com diversas aplicabilidades. O potencial 
farmacológico destes organismos tem sido uma das áreas mais exploradas nomeadamente 
o seu potencial antibacteriano, antifúngico e anticancerígeno. Este trabalho teve por base a 
avaliação do potencial anticancerígeno do composto E13010 F 5.4 isolado da estirpe de 
cianobacteria marinha Synechocystis salina LEGE 06099. Pretendeu-se assim explorar 
mecanismos moleculares e bioquímicos subjacentes à bioatividade detetada em células 
cancerígenas humanas, especificamente nas linhagens de carcinoma do cólon RKO e HT-
29. 
O isolamento do composto foi realizado a partir de biomassa da estirpe de cianobactéria, 
obtida por cultura em grande escala. Para obtenção do composto procedeu-se ao 
fracionamento, confirmação e isolamento por ressonância magnética nuclear (RMN), 
cromatografia em camada fina (TLC) e cromatografia líquida de alta eficiência (HPLC).  
Foram realizados ensaios de viabilidade celular baseados na redução do brometo 3-(4.5-
dimetiltiaziol-2-il)-2.5-difeniltetrazolio (MTT) para avaliar o potencial citotóxico do 
composto. Da bateria de linhagens celulares RKO (carcinoma do cólon), HT-29 
(adenocarcinoma colorretal), MG-63 (osteossarcoma) e T47D (carcinoma da mama) foram 
selecionadas as linhas celulares RKO e HT-29 para elucidação dos mecanismos de 
citotoxicidade. 
Para a avaliação dos mecanismos envolvidos na citotoxicidade as linhagens celulares RKO 
e HT-29 formam expostas ao composto e foi realizada uma bordagem em termos de 
genómica por expressão de mRNA de genes envolvidos na apoptose e ciclo celular por 
PCR em Tempo Real e uma abordagem em termos de proteómica por separação de 
proteínas por eletroforese bidimensional (2DE). Para a expressão de mRNA foram 
selecionados os genes RPL8, HPRT1, VDAC, SHMT2, CCNE, CCNB1, P21CIP, BCL-2 e 
BAD, para proteómica os pontos isoeléctricos entre 3 – 10 e massas moleculares de 19 -
117 kDa foram separados por géis de poliacrilamida (2DGE). 
Os resultados do MTT confirmaram a redução da viabilidade celular. Os resultados de RT-
PCR para a expressão de genes estudados não se mostraram completamente elucidativas. 
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Para a linhagem celular RKO verificou-se uma redução na expressão do gene P21CIP, uma 
tendência para a redução na expressão do gene BAD e um aumento na expressão do gene 
CCNB1, o que aponta para um esforço pela proliferação celular. Na linhagem HT-29 
verificou-se um aumento na expressão do P21CIP e BAD o que poderá explicar a redução 
da viabilidade celular. Os resultados de 2DGE apontam para padrões de proteómica com 
alterações nos diferentes spots nas células tratadas e no controlo com diferenças 
qualitativas e quantitativas, e diferenças na resposta entre RKO e HT-29. 
 
Palavras Chave: cianobactéria, picocianobactéria, Synechocystis salina, potencial 
anticancerígeno, genómica, proteómica 
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Abstract 
In recent years marine biotechnology has revealed a crucial role in the future of 
bioindustry. Among the many marine resources, cyanobacteria have shown great potential 
in the production of bioactive compounds with diverse applicability. The pharmacological 
potential of these organisms has been one of the most explored areas in particular its 
antibacterial, antifungal and anticancer potential. This work was based on the assessment 
of potential anticancer compound E13010 F 5.4 isolated from marine cyanobacteria strain 
Synechocystis salina LEGE 06099. Thus the aim of this work was to explore molecular 
and biochemical mechanisms underlying the bioactivity detected in human cancer cells, 
specifically in lines RKO colon carcinoma and HT-29. 
The isolation of the compound was performed from biomass obtained by large-scale 
culture. To obtain the compound fractionation was carried and confirmation and isolation 
performed by Nuclear Magnetic Resonance (NMR), Thin Layer Chromatography (TLC) 
and High-Performance Liquid Chromatography (HPLC). 
Cell viability assays were performed based on reduction of 3- (4,5-dimetiltiaziol-2-yl) -2,5-
diphenyltetrazolium bromide (MTT) to assess the cytotoxic potential of the compound. 
From the battery of cell lines RKO (colon carcinoma), HT-29 (colorectal adenocarcinoma), 
MG-63 (osteosarcoma) and T47D (breast carcinoma) the cell lines RKO and HT-29 were 
selected for elucidation of mechanisms of cytotoxicity. 
For the elucidation of the mechanisms involved in cytotoxicity the cell lines RKO and 
HT29 were exposed to the compound. A genomic approach based in the mRNA expression 
of genes involved in apoptosis and cell cycle by Real-Time PCR and a proteomic approach 
based on the separation of proteins by two-dimensional electrophoresis (2DGE) was 
performed. For mRNA expression were selected the genes RPL8, HPRT1, VDAC, 
SHMT2, CCNE, CCNB1, P21CIP, BCL-2 and BAD and for proteomics isoelectric 
focussing between 3 – 10 and molecular weight of 19 – 117 kDa separated by 
polyacrylamide gels (2DGE). 
The MTT results confirmed the reduction of the cell viability. The RT-PCR results for the 
expression of genes studied were not yet fully elucidative. For the cell line RKO there was 
a significant reduction in the expression of the gene P21CIP, and a tendency for reduction 
in the BAD gene expression and for increased expression of gene CCNB1, pointing to an 
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effort for cell proliferation. In HT-29 cell line, there was a tendency for increase in the 
expression of P21CIP and BAD, which may explain the reduction in cell viability. The 
2DGE results indicate proteomic patterns with differentially altered spots in the treated and 
control cells with both qualitative and quantitative differences, and differences in response 
between the RKO and HT-29 cell lines.  
 
 
Key word: cyanobacteria, picocyanobacteria, Synechocystis salina, anticancer potential, 
genomics, proteomics 
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I. Introduction 
1. Cyanobacteria: generalities 
The cyanobacteria (blue–green algae) are important primary producers of marine, estuarine 
and fresh water ecosystems and producers of active secondary metabolites that range from 
toxins, to allelopatic compounds and compounds with pharmacological potential (1-4). 
Cyanobacteria are photoautotrophic gram-negative prokaryotes with the capacity to 
perform oxygenic photosynthesis, nitrogen fixation and carbon recycling. In fact, 
cyanobacteria are very important in biogeochemical cycles, as they are responsible for 
about 30% of global primary production, especially in the central oceans (5).  
Cyanobacteria are an ancient monophyletic phylum of the Bacteria domain. It is 
considered that these organisms developed oxygenic photosynthesis 2.5–3.5 billion years 
ago and this capacity was subsequently transferred into eukaryotes via endosymbiosis, 
leading to the appearance of eukaryotic algae and plants (5-7). Latest genome analyses 
seem to point that the primary endosymbiont was most closely related to the current 
filamentous strains (5, 8). As cyanobacteria are photoautotrophic organisms, they only 
need light, water and some inorganic nutrients. As a result, cyanobacteria became 
dominant organisms with major impacts on geochemical processes of our planet. During 
the massive development of cyanobacteria, oxygen was generated in the atmosphere, 
which enabled the rise of oxygen-dependent organisms that exists today. This wide range 
of habitats reflects the impressive capability of cyanobacteria to acclimate to changes of 
many different environmental factors (5, 9). Probably the reason to adapt is based on the 
simple genome (catching many mutations) and the asexual reproduction mode and 
inhabiting a multiplicity of environments worldwide, a result of its morphological and 
physiological diversity (1, 2, 10).  
Taxonomically the cyanobacteria can be classified “botanical” or “bacterial” (10). The 
actualized taxonomic botanical system of classification uses morphological, biochemical 
and molecular characters, cyanobacteria has been grouped into five orders, Chroococcales 
(subsections I), Pleurocapsales (subsections II), Oscillatoriales (subsections III), 
Nostocales (subsections IV) and Stigonematales (subsections V), with correspondence to 
the five subsections proposed in the Bergey’s Manual of Systematic (10-13).  
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Cyanobacteria correspondent to subsections I and II are unicellular. The subsections I are 
divided by binary fission, however the subsections II are multiple fission. The subsections 
III, a few filamentous strains, they have not cell differentiation. Although, the subsections 
IV and V (filamentous strains, have a capacity to differentiated in heterocysts and akinetes. 
The subsections V are capable to divide in multiple planes (10). 
In the last years marine biotechnology has revealed to be a crucial key in future bioindustry 
(14). Among many marine resources, cyanobacteria have a great importance in marine 
biotechnology, namely due to the high potential in producing potential pharmacological 
compounds such as antiviral (12, 15-17), antibacterial, antifungal and anticancer (Table 1) 
(1, 18). Natural products are screened frequently for the treatment of various diseases, 
including marine products. Some marine compounds were approved by the Food and Drug 
Administration (FDA) for treatment of various cancers; among the FDA approved 
compounds are anticancer agent derived from cyanobacteria, and several other compounds 
from cyanobacteria are in different phases of clinical trials (19). Cyanobacteria are also 
known for their role in the nutrient cycling and are therefore very important in ecosystems 
poor in nutrients both in freshwater and sea (14, 20).  
Morphologically, cyanobacteria are surrounded by two membranes. The cell wall is 
enclosed by an outer membrane that surrounds the periplasmic space, whereas the 
cytoplasmic membrane surrounds the cytoplasm. Inside the cytoplasm, it has a third 
membrane system, a thylakoid membrane that has the photosynthetic complexes. 
Furthermore, the respiratory electron transport chain is also mostly situated at the thylakoid 
membranes (5). 
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Table 1 Marine cyanobacterial compounds with potential anticancer properties. Adapted from Costa et al., 
2012 (18). 
Compound Source Class of compound 
Anticancer 
activity 
References 
Ankaraholide A Geitlerinema 
Glycosilated 
swinholide 
Lung cancer and 
breast carcinoma 
(21) 
Apratoxin A 
Lyngbya 
majuscula 
Cyclic depsipeptide 
Oral epidermoid 
cancer, colon 
cancer, 
osteosarcoma 
and cervical 
carcinoma 
(22-24) 
Apratoxins B–C Lyngbya sp. Cyclic depsipeptide 
Oral epidermoid 
cancer and colon 
cancer 
(22) 
Apratoxin D 
Lyngbya 
majuscula 
and Lyngbya 
sordida 
Cyclic depsipeptide Lung cancer (25) 
Apratoxin E 
Lyngbya 
bouilloni 
Cyclic depsipeptide 
Osteosarcoma, 
colon 
adenocarcinoma 
and epithelial 
carcinoma 
(24) 
Apratoxins F–G 
Lyngbya 
bouilloni 
Cyclic depsipeptide 
Lung cancer and 
colorectal cancer 
 
Aurilide B 
Lyngbya 
majuscula 
Cyclic depsipeptide Lung cancer  
Aurilide C 
Lyngbya 
majuscula 
Cyclic depsipeptide Lung cancer (26) 
Belamide A Symploca sp. Linear tetrapeptide Colon cancer (26) 
Bisebromoamide Lyngbya sp. Peptide 
Epithelial 
carcinoma 
(27) 
Biselyngbyaside Lyngbya sp. Glicomacrolide 
Epithelial 
carcinoma, 
central nervous 
system cancer 
and lung cancer 
(28) 
Calothrixin A Calothrix 
Pentacyclic 
Indolophenanthridine 
Epithelial 
carcinoma and 
leukemia 
(29) 
Calothrixin B Calothrix 
Pentacyclic 
Indolophenanthridine 
Epithelial 
carcinoma and 
leukemia 
(30) 
Caylobolide A 
Lyngbya 
majuscula 
Macrolactone 
Colon 
carcinoma 
(31, 32) 
Caylobolide B 
Phormidium 
spp. 
Macrolactone 
Colorectal 
adenocarcinoma 
and cervical 
carcinoma 
(32, 33) 
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Coibamide A 
Leptolyngbya 
sp. 
Cyclic depsipeptide 
Lung cancer, 
breast cancer, 
melanoma, 
leukemia and 
astrocytoma 
(34) 
Cryptophycin 1 Nostoc spp. Cyclic depsipeptide 
Mammary 
adenocarcinoma, 
mammary 
carcinoma, 
ovarian 
carcinoma, 
leukemia, colon 
carcinoma and 
cervical 
carcinoma 
(34, 35) 
Dolastatin 10 Symploca sp. Linear Pentapeptide 
Lung carcinoma, 
prostate cancer, 
lymphoma and 
leukemia 
(36-39) 
Dolastatin 12 
Leptolyngbya 
sp. 
Cyclic depsipeptide Lung carcinoma (36) 
Dragonamide 
Lyngbya 
majuscula 
Lipopeptide 
Lung epithelial 
adenocarcinoma, 
colon 
adenocarcinoma 
and melanoma 
(36) 
Ethyl Tumonoate 
A 
Oscillatoria 
margaritifera 
Peptide Lung cancer (40) 
Hoiamide A 
Assemblage of 
Lyngbya 
majuscule and 
Phormidium 
gracile 
Cyclic depsipeptide Lung cancer (41) 
Hoiamide B 
Cyanobacterial 
sample 
Cyclic depsipeptide Lung cancer (41) 
Homodolastatin 
16 
Lyngbya 
majuscula 
Cyclic depsipeptide 
Esophageal 
cancer and 
cervical cancer 
(42) 
Isomalyngamide 
A and A-1 
Lyngbya 
majuscula 
Fatty acid amides Breast cancer (43) 
Jamaicamides A 
– C 
Lyngbya 
majuscula 
Polyketide-Peptides Lung cancer (44) 
Kalkitoxin 
Lyngbya 
majuscula 
Lipopeptide 
Colon 
carcinoma 
(45) 
Lagunamide C 
Lyngbya 
majuscula 
Cyclic depsipeptide 
Lung 
adenocarcinoma, 
prostate cancer, 
ileocecal, 
colorectal cancer 
and ovary cancer 
(46) 
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Largazole Symploca sp. Cyclic depsipeptide 
Breast cancer, 
osteosarcoma, 
lung cancer and 
colorectal 
carcinoma 
(46, 47) 
Lyngbyabellin A 
Lyngbya 
majuscula 
Cyclic depsipeptide 
Nasopharyngeal 
carcinoma and 
colon 
adenocarcinoma 
(36, 48) 
Lyngbyaloside Lyngbya sp. Glicomacrolide 
Nasopharyngeal 
carcinoma and 
colon 
adenocarcinoma 
(49) 
Majusculamide 
C 
Lyngbya 
majuscula 
Cyclic depsipeptide 
Ovarian 
carcinoma, 
kidney cancer, 
lung cancer, 
colorectal cancer 
and gliobastoma 
(50) 
Malevamide D 
Symploca 
hydnoides 
Peptide ester 
Lung cancer, 
colon cancer and 
melanoma 
(51) 
Malyngamide 2 
Lyngbya 
sordida 
Fatty acid amine Lung cancer (52) 
Malyngamide C, 
J and K 
Lyngbya 
majuscula 
Fatty acid amine Lung cancer (53) 
Malyngolide 
dimmer 
Lyngbya 
majuscula 
Cyclodepside Lung cancer (54) 
Nostocyclopepti-
de A1 and A2 
Nostoc sp. Cyclic heptapeptides 
Oral epidermoid 
cancer and colon 
cancer 
(55) 
Obyanamide 
Lyngbya 
confervoides 
Cyclic heptapeptides 
Oral epidermoid 
cancer and colon 
cancer 
(56) 
Palauamide Lyngbya sp. Cyclic depsipeptide 
Cervical 
carcinoma, lung 
adenocarcinoma, 
gastrocarcinoma 
and oral 
epidermoid cancer 
(57, 58) 
Palmyramide A 
Lyngbya 
majuscula 
Cyclic depsipeptide Lung cancer (59) 
Pitipeptolides A–
B 
Lyngbya 
majuscula 
Cyclic depsipeptide 
Colon cancer, 
colon 
adenocarcinoma 
and breast 
cancer 
(60, 61) 
Pitipeptolide C 
Lyngbya 
majuscula 
Cyclic depsipeptide 
Colon cancer, 
colon 
adenocarcinoma 
(61) 
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and breast 
cancer 
Pitiprolamide 
Lyngbya 
majuscula 
Cyclic depsipeptide 
Colorectal 
carcinoma and 
breast 
adenocarcinoma 
(62) 
Pseudodysidenin 
Lyngbya 
majuscula 
Lipopeptide 
Lung 
adenocarcinoma, 
colon 
adenocarcinoma 
and melanoma 
(63) 
Somocystinamide 
A 
Lyngbya 
majuscula 
Lipopeptide 
Leukemia, lung 
carcinoma, 
melanoma and 
myeloma 
(64) 
Symplocamide Symploca sp. Cyclic peptide Lung cancer (65) 
Symplostatin 1 
Symploca 
hydnoides 
Linear Pentapeptide 
Breast 
carcinoma, 
ovarian 
carcinoma and 
epidermoid 
carcinoma 
(66, 67) 
Tasiamide Symploca sp. Cyclic peptide 
Oral epidermoid 
cancer and colon 
cancer 
(68) 
Tasiamide B Symploca sp. Peptide 
Oral epidermoid 
cancer  
(69) 
Tasipeptins A-B Symploca sp. Cyclic depsipeptides 
Oral epidermoid 
cancer  
(70) 
Ulongapeptin Lyngbya sp. Cyclic depsipeptides 
Oral epidermoid 
cancer  
(71) 
Veraguamides A-
G 
Symploca cf. 
Hydnoides 
Cyclic depsipeptides Lung cancer (72) 
Wewakazole 
Lyngbya 
sórdida 
Cyclic depsipeptides Lung cancer (52) 
Wewakpeptins 
Lyngbya 
semiplena 
Depsipeptides Lung cancer (73) 
 
1.1. Picocyanobacteria 
Picoplankton is constituted by organisms with a size range between 0.2 and 2 µm (21, 22). 
Small unicellular cyanobacteria in the size range of picoplankton represent ubiquitous 
components of pelagic ecosystems (23) where they contribute substantially to both 
phytoplankton biomass and production in marine and freshwater ecosystems (24). This 
small organisms are found in large quantities in both freshwater and marine water 
throughout the world (25, 26) and includes prokaryotic and eukaryotic autotrophs and 
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heterotrophs being the predominant  constituents, the cyanobacteria and heterotrophic 
bacteria. Picophytoplankton is responsible for most of the total primary production in lakes 
and oceans (27) and the production of heterotrophic bacteria is often related to this primary 
production (28, 29).  
Picoplanktonic cyanobacteria include isolates of the Chroococcales order, particularly the 
picocyanobacterial genera Cyanobium, Prochlorococcus, Synechocysti and Synechococcus. 
Cyanobium consists of solitary oval cells without gelatinous envelopes. Most small 
cyanobacteria rod that exist in natural freshwater or marine plankton are classified into 
Synechococcus group and are identified as Synechococcus sp. or Cyanobium sp.. 
According Rippka et al (30) the genus Cyanobium was secreted from Synechococcus based 
of different mean DNA base composition and sensitivity to various cyanophages. This 
proves that exist a close relationship between Cyanobium and Synechococcus. Cell division 
proceeds by perpendicular binary fission (usually cleavage), which is sometimes 
asymmetrical (22). The genus marine Synechococcus is very common in all oceans, for this 
reason is the base of the marine food web because it is the primary food producers in 
coastal environments (31).  
Prochlorococcus, like Synechococcus, also exists in large quantities in the oceans.  They 
are unicellular and have different photosynthetic pigments. Its strains are phenotypically 
distinct and many have not yet been described (32-35). 
Marine picoplanktonic cyanobacteria are extremely difficult to isolate. For this reason, 
several methods have been used to obtain axenic clonal cultures: UV radiation, chemical 
treatments using phenol, antibiotics and sulfide, and physical treatments such as 
micropipette washing or plating methods (36-40). Picocyanobacteria are more easily 
isolated using  agarose and low-melting temperature agarose to obtain colonies of 
picoplanktonic cyanobacteria and their axenic clonal cultures from unialgal bacterized 
cultures by plating method (21). 
1.1.1. Picocyanobacteria bioactive potential 
In the last years marine cyanobacteria have been in the frontline for the isolation of 
bioactive compounds. Also it is currently using natural sources such as marine products to 
produce new complexes drugs (41, 42).  The interest on marine biotechnology was 
enhanced by the results of some studies, which indicated that marine microorganisms are 
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substantially involved in the biosynthesis of marine natural products previously isolated 
from macroorganisms such as invertebrates (43, 44). The cultivated marine 
microorganisms, particularly actinomycetes and fungi, are well known for their production 
of bioactive metabolites (45). Cyanobacteria (blue-green algae) are also identified as a 
promising source of biochemically active natural products (46, 47).  
Cyanobacteria produce a wide variety of secondary metabolites that exhibit a variety of 
biological activities and chemical structures. On one hand, some cyanobacterial secondary 
metabolites may have toxic effects on living organisms, such as common toxins like 
microcystins (48, 49) or may have ecological roles such as allelopathy and may be used for 
biotechnological applications such as algaecides, herbicides and insecticides (50). On the 
other hand, cyanobacteria have become a new source of active compounds showing 
interesting biological activities ranging from antibiotics, immunosuppressants, anticancer, 
antiviral and anti-inflammatory to proteinase-inhibiting agents (48, 49, 51). Studies 
oriented to the production of compounds that could be used as antibiotics and drugs against 
important diseases such as cancer found that cyanobacteria strains of the genera 
Synechocystis and Synechococcus caused growth inhibition of Gram-positive bacteria (52) 
and apoptotic effects against the myelogenic human leukaemia cell line HL-60 and in the 
human neuroblastoma cell line SH-SY5Y (3).  In all the reported cases, although the 
bioactive compounds were not identified, the results support the hypothesis that 
picocyanobacteria also produce biologically active compounds. 
The toxins of cyanobacteria constitute a most important source of natural product toxins 
that are found in surface supplies of both freshwater and seawater (53-55). Marine 
cyanobacteria have been extensively studied for the production of compounds with 
pharmacological applications (56), however, until a few years studies mainly focused on 
large filamentous forms (57). In the last years a considerable effort has been applied in the 
study of picocyanobacteria as a source of bioactive compounds (3). In contrast to 
filamentous forms, picoplanktonic cyanobacteria occur in low densities under normal 
conditions and thus have been largely overlooked for biological activities. 
Bioassays-guided fractionation is a methodology that has been efficaciously used for the 
isolation and identification of marine natural compounds, since it allows the rapid 
recognition of the active fractions, which may contain compounds of interest (3, 58-60). 
Based on this methodology several picocyanobacteria strains revealed potential as a source 
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of bioactivity interesting compounds. In Table 2 a compilation of bioactivities of 
picocyanobacteria is shown based on scientific literature. 
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Table 2 Bioactivities described to picocyanobacteria. 
Genera Origin Bioactivity Assay Model tested References 
Synechococcus sp. Temperate coastal 
Neurological and behavioural 
changes 
Light-dark preference 
test (scototaxic test), is a 
method to measure 
anxiety in fish and 
whether pharmacological 
compound alter anxiety 
Black perch (Embiotoca 
jacksoni) 
(31) 
Cyanobium sp. 
LEGE 06098 
Portuguese 
Coast 
Anticancer activity MTT and LDH Cancer cell lines (3) 
Toxicity and developmental 
toxicity 
Artemia salina mortality 
and embryonic 
development of 
Paracentrotus lividus 
 
 
Artemia salina  
Paracentrotus lividus 
(61) 
Cyanobium sp. 
LEGE06113 
Anticancer activity 
MTT and LDH 
Cancer cell lines (3) 
Antitumour activity of 
hierridin B, a secondary 
metabolite 
Hepatocellular carcinoma cell 
line HepG2, colon 
adenocarcinoma cell line HT-29, 
neuroblastoma cell line SH-
SY5Y, breast carcinoma cell line 
T47D, normal prostate cell line 
PNT2, breast adenocarcinoma 
SKBR3, colon carcinoma RKO, 
osteosarcoma MG-63 
(62) 
Cyanobium sp. 
LEGE 07175 
Anticancer activity Cancer cell lines (3) 
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Continuation Table 2 Bioactivities described to picocyanobacteria. 
Genera Origin Bioactivity Assay Model tested References 
Cyanobium sp. 
LEGE 07186 
Portuguese 
Coast 
Anticancer activity MTT and LDH Cancer cell lines (3) 
Cyanobium sp. 
LEGE 06137 
Cyanobium sp. 
LEGE 06097 
Cyanobium sp. 
LEGE 06139 
Synechocystis salina 
LEGE 06099 
Synechocystis salina 
LEGE 06155 
Synechocystis salina 
LEGE 07173 
Synechococcus  
nidulans 
LEGE07171 
Synechococcus sp. 
LEGE 07172 
Synechococcus sp. 
LEGE 06005 
Synechococcus sp. 
LEGE 06026 
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In a recent study of cyanobacteria isolated from the Portuguese coast, twenty eight strains 
were tested in eight cancer cell lines, which were selected as representative of various 
human tumours. From this panel of marine cyanobacteria 15 strains belong to the 
picocyanobacteria genera Cyanobium, Synechocystis and Synechococcus (3)  and 
demonstrated potential anticancer activities by the MTT cytotoxicity assay.  
Some strains belonging to the genera Cyanobium, Synechocystis, Synechococcus and 
Leptolyngbya were shown to have a potential source of bioactive compounds based on  
screenings for anticancer activity (Table 1), based on screenings with mammals (63), 
invertebrates (64, 65), virus, bacteria and cell lines like HT-29 and RKO (52, 66).  
The marine picocyanobacterium Prochlorococcus produces a complex group of polycyclic 
lantipeptides (67). The unicellular, cyanobacterium Prochloron didemni also produces e a 
varied set of secondary metabolites, including cyclic peptides and unusual fatty acids (68). 
The NMR-based isolation of hierridin B from the picocyanobacterium Cyanobium sp. 
LEGE 06113 was reported by Leão et al (62) which had been isolated from the Atlantic 
coast of Portugal. The compound had previously been isolated from the marine 
filamentous cyanobacterium Phormidium ectocarpi (SAG 60.90) strain and showed 
antiplasmodial activity.  
A recent study of cyanobacterial genomes (69) indicated the presence of biosynthetic gene 
clusters, mostly of the polyketide synthetase (PKS) among picocyanobacteria genera 
Cyanobium, Synechococcus and Prochlorococcus (62), which could be involved in the 
pathways leading to the production of bioactive compounds. 
Although most of the research work present in the literature with a focus on bioactive 
compounds from marine picopcyanobacteria are performed with extracts only, the results 
point to picocyanobacteria of the genera Cyanobium, Synechocystis, Synechococcus as 
potentially interesting in the field of natural products. 
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2. Cancer 
Cancer always represented for the scientific community the research area of great interest 
due to the high mortality rate that occurs worldwide and need to search for new treatments 
(70). The emergence of a cancer involves high damage to the patient health because the 
treatment itself used, radiation and chemotherapy, as appropriate, ultimately cause 
secondary damage throughout the body, to decrease the patient quality of life (71). As a 
result of various causes that may lead to the development of a cancer, this can affect 
various areas of the body, resulting in an enormous variety of cancers that affect humans 
today. Among the various types of cancer, based on the number of cases and deaths 
worldwide lung cancer, breast cancer, colorectal cancer, liver cancer and stomach cancer 
are the most prevalent ones (72, 73). 
It is important, through the high impact that this concept presents to society, to understand 
how cancer form and how proliferates. One of the first studies on cancer cell metabolism 
goes back to the 50s of the twentieth century, when Otto Warburg showed that these cells 
consumed high amounts of glucose, producing high levels of lactate, even under aerobic 
conditions, the so-called effect of Warburg (74). The normal use of our organism cells to 
obtain energy, i.e., ATP, mitochondrial oxidative phosphorylation level with superior 
energy efficiency to lactic fermentation, used by the cancer cells. However, the use of this 
power generation process is extremely fast (75). Additionally cancer cells exhibit, in some 
cases, mitochondrial dysfunction level even with mitochondrial ATP production in 
considerable quantity level (76). Thus, a change in the cancer cells translates into changes 
in mitochondrial metabolism, with the expression changes of these organelles major 
components (77). 
There are mechanisms that can be seen as markers of tumour progression, including: 1) 
high capacity of resistance to the apoptosis process with replication ability to almost 
endless manner and without any control the cell cycle level; 2) induction of the 
angiogenesis process; 3) invading other parts of the body (metastasis) (78, 79).  
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II. Objectives 
Marine cyanobacteria are well known as a source of bioactive compounds with anticancer 
potential. We aim with this work to characterize the toxicological properties of the marine 
cyanobacteria (Synechocystis salina LEGE 06099) compound E13010 F 5.4 by 
investigating the biochemical and molecular events underlying the bioactivity detected in 
human cancer cells, specifically in colon carcinoma (RKO) and colorectal adenocarcinoma 
(HT-29). The compound E13010 F 5.4 is still under structural characterization but it is 
already know to be a glycolipid.  The specific objects of the work were the following: 
1. To perform cytotoxicity assays with a selection of cancer cell lines (RKO, HT-29, 
MG-63, and T47D) in a concentration range of the compound E13010 F 5.4 (30 
µg/mL, 3 µg/mL, 0.3 µg/mL and 0.003 µg/mL);  
2. To analyze the mRNA expression of genes involved in the cell cycle (CCNB1, 
CCNE and P21CIP), in apoptosis (BCL-2 and BAD) and others processes (VDAC 
and SHMT2) by Real Time PCR;  
3. To perform a non-target approach based on proteomics by two-dimensional gel 
electrophoresis (2DGE) and identification of differentially expressed spots by 
matrix-assisted laser desorption ionization time-of-flight/time-of-flight (MALDI-
TOF/TOF), in order to get new insights into the mode of action of the compound.   
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III. Material and Methods 
1. Cyanobacterial Strain and Culture 
In this work the strain Synechocystis salina LEGE 06099 was selected according to 
previous results (80). From this strain the compound E13010 F 5.4 was found to induce 
cytotoxicity to the cancer cell lines RKO (colon carcinoma) and HT-29 (colorectal 
adenocarcinoma). This strain is part of the cyanobacteria culture collection of the 
Laboratory of Ecotoxicology, Genomics and Evolution (LEGE) at the Interdisciplinary 
Center of Marine and Environmental Research (CIIMAR). For this work the culture of this 
cyanobacteria was mandatory in order to obtain biomass for the isolation of the compound. 
The compound is still under structural characterization but it is already known that is a 
glycolipid. 
The cyanobacteria strain was cultured in large scale in Z8 medium supplemented with     
20 g/L, at a temperature of 21 ˚C, brightness of 25 µmol m-2 s-1, a photoperiod of 14h/10h 
(day/night) and with constant aeration, being the air filtered through a 0.2 μm filter (Sterile 
Syringe Filter w/ 0.2 μm Cellulose Acetate Membrane – VWR International) to prevent 
contamination (Figure 1). 
In exponential phase the biomass was concentrated by centrifugation at 4600 rpm for 10 
minutes at 4˚C.  The concentrated biomass was washed twice with distilled water to 
remove sodium chloride, centrifuged again and stored at -20 °C. All biomass was 
lyophilized, weighed and stored at -20 °C until used. 
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Figure 1 Process for obtaining biomass of LEGE06099. 
  
Transfer culture of Erlenmeyer 
flask (100 mL) for ballons (6L) 
 
Centrifugation of cyanobacteria 
to obtain biomass 
Beginning culture of LEGE06099 
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2. Cyanobacterial Fractioning to pure compound 
The extract procedure and fractionation to obtain the pure compound was the same 
described by Afonso, 2014 (80). A cyanobacterial crude extracts was prepared with the 
lyophilized material by employing an apparatus assembled as shown in Figure 2. The 
biomass (28.3 g) was extracted with a mixture of dichloromethane:methanol 
(DCM:MeOH) (2:1, v/v) (40 mL per gram of biomass). This mixture was allowed to 
remain for 10 minutes at room temperature, while stirring and homogenizing with a 
spatula. Following, the vacuum was turned on as the solvent contents were poured into the 
Büchner funnel and the resulting liquid phase was collected in a round bottom (RB) flask. 
Before starting a new step in the extraction, the biomass that had been poured was retained 
in a cheese cloth and recovered for a new extraction. This process was repeated two more 
times under these conditions and then seven times at approximately 40ºC with the use of a 
hotplate, for 20 minutes each, with constant stirring. Following extraction the solvents 
were removed in a rotary evaporator. The content of the RB flask was then resuspended 
and transferred to a pre-weighed glass vial, which was dried in a rotary evaporator. An 
amount of 3.9679 g of crude extract was obtained.   
 
 
Figure 2 System assemblage for organic extraction. 
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The crude extract was then subjected to normal phase (silica gel 60, 0.0015-0.040 mm, 
Merck, KgaA, Damstadt, Germany) vacuum liquid chromatography (VLC) (Figure 3). A 
gradient of solvents from 9:1 hexane:ethyl acetate (Hex:EtOAc) to 100% EtOAc to 100% 
MeOH was used in this VLC (Table 3), so as to obtain fractions with increased polarity. 
 
 
Figure 3 Apparatus for the vacuum liquid chromatography (VLC). 
 
The crude extract was dissolved in 10% EtOAc in Hexane with help of ultrasounds and 
loaded onto Whatman No1 filter paper placed on top of the silica column and the solvent 
mixtures were added stepwise, according to Table 3, without allowing the silica surface to 
become dry and resulting in ten fractions A, B, C, D, E, F, G, H, Hx and I. Silica on the SI 
chromatography column was activated with 10% EtOAc in Hexane. The crude extract was 
placed in the column, followed by hexane, which was collected in an Erlenmeyer flask, 
until a yellow coloration reached ¾ of the column.  
  
Glass filtration funnel 
Whatman No1filter paper 
Silica gel 60 
Vacuum adapter 
Vacuum pump 
RB flask 
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Table 3 Solvents volumes added to obtain 10 fractions. 
Fraction Mixture of solvents Hex EtOAc MeOH Total 
A 10% EtoAc + 90% Hex 450 mL 50 mL 0 mL 500 mL 
B 20% EtoAc + 80% Hex 200 mL 50 mL 0 mL 250 mL 
C 40% EtoAc + 60% Hex 150 mL 100 mL 0 mL 250 mL 
D 50% EtoAc + 50% Hex 125 mL 125 mL 0 mL 250 mL 
E 60% EtoAc + 40% Hex 100 mL 150 mL 0 mL 250 mL 
F 80% EtoAc + 20% Hex 50 mL 200 mL 0 mL 250 mL 
G 100% EtoAc 0 mL 250 mL 0 mL 250 mL 
H 25% MeOH + 75% EtoAc 0 mL 187,5 mL 62,5 mL 250 mL 
HX 25% MeOH + 75% EtoAc 0 mL 187,5 mL 62,5 mL 250 mL 
I 100 % MeOH 0 mL 0 mL 250 mL 250 mL 
 
All the solvents in the fractions were evaporated in the rotary evaporator, and the sediment 
resuspended with the less volume possible of chloroform. This mixture was then 
transferred to 16 mL glass vials previously marked and weighted, evaporated with N2 
stream drying apparatus and stored at -20 ˚C. 
After the fractioning Nuclear Magnetic Resonance spectroscopy (NMR) and Thin Layer 
Chromatography (TLC) were performed.  
2.1. Nuclear Magnetic Resonance spectroscopy (NMR) 
The NMR analysis was used to confirm the presence of the compound in the fractions. The 
samples were prepared in a thin-walled glass tube Norell Standard Series™ 5mm tubes 
(Sigma-Aldrich) with deuterochloroform (CDCl3) (Sigma-Aldrich). NMR was performed 
in Centro de Materiais da Universidade do Porto (CEMUP).  
2.2. Sub-fractionation of Fraction F 
After knowing that the compound of interest is located in the Fraction F a Sub-
fractionation of this fraction was performed as shown in Figure 4.  
Molecular and biochemical mechanisms involved in the toxicity of a marine cyanobacteria compound on 
cancer cell lines 
28 
 
 
Figure 4 System assemblage for the normal phase column chromatography of fraction F. 
 
The fraction F was dissolved in a mixture of 30% EtoAc in hex and placed on top of the 
silica column. A gradient of solvent mixtures was applied on the silica column with 
increasing in polarity, to better separate the compounds (Table 4). This chromatography 
was performed by gravity, 75 fractions were collected and analysed by TLC. 
 
Table 4 Gradient used for the normal phase gravity column chromatography of fraction F. 
Collection tubes EtOAc Hex MeOH 
Total 
Volume 
1 – 4 30% 70% - 250 mL 
5 40% 60% - 100 mL 
6 40% 60% - 100 mL 
7 – 8 40% 60% - 100 mL 
9 – 24 40% 20% - 500 mL 
25 – 30 40% - - 250 mL 
31 – 34 80% - - 250 mL 
35 – 41 100% - - 250 mL 
42 – 52 75% - 25% 500 mL 
53 – 63 75% - 25% 250 mL 
63 – 75 75% - 25% 250 mL 
 
 
Chromatography column 
Silica gel 60 
Sand 
Cotton ball 
Collection tube 
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2.3. Thin Layer Chromatography (TLC) 
For TLC 10 µL of samples in were placed in TLC silica gel 60 F254 plates. Plates were 
placed in a tank mixture of solvents, EtOAc in Hex (50:50), observed in the UVs (366 nm 
absorbance) and the areas to be marked up the compounds of interest. The silica plates 
were immersed in the acid phosphomolybdic acid (PMA DIP) and put on a hotplate until 
they see the compounds.  
2.4. HPLC for the isolation of the compound 
The isolation of the compound was performed in HPLC following the protocol described 
in Afonso, 2014. This step was not performed during this thesis. 
 
3. Cell Culture and Cytotoxicity Assays 
Cytotoxic assays were firstly performed with the human colon adenocarcinoma cell line 
HT-29 and RKO, the osteosarcoma cell line MG-63 and the breast carcinoma cell line 
T47D in order to infer about selective toxicity. HT-29 and T47D cells were purchased 
from Sigma-Aldrich; MG-63 and RKO cells were obtained from the American Type 
Culture Collection (ATCC). The selection of this cancer cell lines was based in previous 
results of cytotoxicity of the compound in different cell lines (3). 
Cells were cultured in DMEM GlutaMAX medium (Dulbecco’s Modified Eagle Medium 
DMEM GlutaMAX
TM
 – Gibco – Invitrogen), supplemented with 10% (v/v) Fetal Bovine 
Serum (Gibco – Invitrogen), 1% Fungizone (Gibco – Invitrogen) and 1% Penicillin-
Streptomycin (Pen-Strep 100 IU/mL and 10 mg/mL, respectively) (Gibco – Invitrogen). 
Cells were maintained in a humidified incubator at 37 ˚C, with 5% CO2. 
The cytotoxicity of the compound was assessed by the reduction in cell viability measured 
by the reduction of 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT), 
a yellow tetrazole soluble in water, to purple formazan crystals. The reduction of MTT to 
formazan is directly proportional to the mitochondrial activity and consequently cell 
viability. 
Cytotoxicity assays were performed in 96-well plates. All cell lines were seeded at 3.3x10
4 
cel/mL. After 24h of adhesion, cells were exposed to new medium with the compound a 
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range of concentrations of 30 µg/mL, 3 µg/mL, 0.3 µg/mL, 0.03 µg/mL and 0.003 µg/mL 
for 24 and 48 hours. After treatment cells were incubated with 0.05 mg/mL MTT for 3 
hours. At the end of this period, the medium was aspirated and the formazan crystals 
dissolved in 500 µL 100% DMSO (Panreac). The absorbance was read at 550 nm in a Gen 
5™ – Multi – detection Microplate Reader (Biotek).  
From this assays the cancer cell lines RKO and HT-29 were selected to perform genomic 
and proteomic assays. 
3.1. Exposure to cyanobacterial compound E13010 F 5.4 for 
genomics and proteomics 
RKO and HT-29 cells were cultured in 24-well plates (Orange Scientific) at a density 
1x10
6
 cells/mL. After 24 hours of culture, the medium was removed and was replaced by 
medium supplemented with: 1) 20% DMSO (negative control group); 2) 1% DMSO 
(positive control group) and 3) cyanobacteria compound a range of concentrations of       
30 µg/mL; 3 µg/mL; 0.3 µg/mL; 0.03 µg/mL; 0.003 µg/mL. Initially all these 
concentrations were tested in order to select an exposure concentration for the genomics 
and proteomics analyses. Finally, the 30 µg/mL concentration was selected. In all assays 6 
replicates were performed.  In parallel to the exposure of cells for proteomics and 
genomics, cells were exposed to the compound for MTT, using 3 replicates for treatments 
and controls, in order to certificate its cytotoxicity.  
To collect cells after exposure to the compound E13010 F 5.4, the medium was aspirated 
and cells were washed with PBS (250 µL per well). Cells were then trypsinized (0.25% 
Trypsin-EDTA, Gibco – Invitrogen) (200 µL per well) transferred to an 1.5 mL Eppendorf 
tube, centrifuged at 1200 rpm for 5 minutes and stored as cell pellet at -80 °C for posterior 
analysis.  
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4. Gene Expression Analysis 
4.1. RNA isolation and cDNA synthesis  
Total RNA was extracted from the cells exposed to compound and negative control to 
investigate the expression of the mRNA. To do this, we used Total RNA Isolation 
(Macherey-Nagel) kit and chosen protocol was Total RNA purification from cultured cells, 
laser captured cells, or microdissected cryosections with Nucleospin® RNA XS. The 
protocol is based on 10 stages: 1 – supply samples (provide sample such as a pellet of up to 
5 x 10
5
 cells); 2 – lyse and homogenize cells; 3 – add Carrier RNA (it step was not 
performed); 4 – filtrate lysate; 5 – adjust RNA binding condition; 6 – bind RNA; 7 – desalt 
silica membrane; 8 – digest DNA; 9 – wash and dry silica membrane; 10 – elute highly 
pure RNA (used 30 µL of water RNase-free). 
After this process, RNA was quantified with the Qubit® Fluorometer (Invitrogen), using 
two standards and following the manufacturer instructions.  
The quality of the extracted RNA was accessed by 1% agarose gel electrophoresis. RNA 
quality was considered good, if the bands were sharp, with the 28S band being about twice 
as intense as the 18S band.  
Transcription of RNA into cDNA was performed by reverse transcription (RT) using the 
iScript™ Reverse Transcription Supermix for RT-qPCR (Bio-Rad) using oligo (dT) 
primer. 1 µg of total RNA was reverse-transcribed in a 20 µL reaction; 4 µL 5x iScript 
reverse transcription supermix; RNA template (
1000 𝑛𝑔 𝑥 1 µL
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 µg/mL
 ); nuclease-
free water (RNA template – 13 µL). Samples of cDNA were stored at -20˚C. 
4.2. Evaluation of Primer 
The cDNA products were used for analysis of primer performance of a set of selected 
human genes (RPL8, HPRT1, VDAC, SHMT2, CCNE, CCNB1, P21CIP, BCL-2, BAD) 
(Table 5). For performance evaluation in real-time PCR in the conditions given in the next 
paragraph, standard curves were analysed from the diluted cDNA pool. The resulting 
amplification efficiency of the primers should be between 86.4% and 108.2%. The view of 
the melt curve from the RT-PCR analysis monitored the specificity of the performed 
reaction.  
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Primers were previously ready and evaluation had been made in a previous work (81).  
Table 5 Selected primers main information in NCBI (82). 
Name Function 
Primer 
sequence 
Efficiency 
Annealing 
temperature 
RPL8 
(Ribosomal 
protein L8) 
Encodes a ribosomal 
protein that is a part of 
the 60S subunit. 
Forward: 
5’GTGTGGTG
GCTGGAGGT
G3’ 
Reverse: 
3’CGATGTGC
TGGTGGTTGC
5’ 
101,4% 57 ˚C 
HPRT1 
(Hypoxanthine 
Phosphoribosy
l transferase) 
Converts hypoxanthine 
to insonie 
monophosphate and 
guanine to guanosine 
monophosphate. Central 
role on generating purine 
nucleotides. 
Forward: 
5’TGGCGTCG
TGATTAGTGA
TG3’ 
Reverse: 
3’CAGAGGGC
TACAATGTG
ATGG5’ 
96,5% 57 ˚C 
VDAC 
(Voltage-
dependent 
anion channel) 
Encodes a voltage-
dependent anion channel 
protein that is a major 
component of the outer 
mitochondrial 
membrane.  
Forward: 
5’CGGAAGGC
AGAAGATGG
C3’ 
Reverse: 
5’TTGGTGGT
CTCAGTGTTG
G 3’ 
94,6% 57 ˚C 
SHMT2 
(Serine 
hydroxymethy 
transferase 2) 
Encodes the 
mitochondrial form of a 
pyridoxal phosphate-
dependent enzyme that 
catalyzes the reversible 
reaction of serine and 
tetrahydrofolate to 
glycine and 5, 10-
methylene 
tetrahydrofolate, which is 
responsible for glycine 
synthesis. 
Forward: 
5’CTGCGACTTC
CGAGTTGCGATG
3’ 
Reverse: 
5’GGCTGCGTTG
CTGTGCTGAG3’ 
95,1% 57 ˚C 
CCNE 
(Cyclin E1) 
Regulates the subunit of 
CDK2, required for the 
cell cycle G1/S 
transition. 
 
 
Forward: 
5’GTTCTCGG
CTCGCTCCAG
3’ 
 
 
86,4% 57 ˚C 
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Reverse: 
3’CGGTCATC
ATCTTCTTTG
TCAGG5’ 
CCNB1 
(Cyclin B1) 
Essential for the cell 
cycle control at G2/M 
(mitosis) transition. 
Forward: 
5’CTAAGATT
GGAGAGGTT
GATGTC3’ 
Reverse: 
3’CAGGTAAT
GTTGTAGAGT
TGGTG5’ 
91% 57 ˚C 
P21CIP 
(Cyclin-
Dependent 
Kinase 
Inhibitor 1A) 
Binds and inhibits cyclin-
dependent kinase activity 
and blocking cell cycle 
progression. 
Forward: 
5’GGGACAGC
AGAGGAAGA
C3’ 
Reverse: 
3’CGGCGTTT
GGAGTGGTA
G5’ 
96% 55 ˚C 
BCL-2 
(B-Cell CLL/ 
Lymphoma) 
Acts as anti-apoptotic 
regulators that are 
involved in a variety of 
cell activities. The 
proteins encoded reduce 
the release of pro-
apoptotic cytochrome c 
from mitochondrial and 
block caspase 
activations. Have two 
transcripts: alpha and 
beta. (We used the alpha 
transcript.) 
Forward: 
5’GTGTGGAG
AGCGTCAAC
C3’ 
Reverse: 
5’CTTCAGAG
ACAGCCAGG
AG3’ 
108,2% 55 ˚C 
BAD 
(BCL2-
Associated 
Agonist Of 
Cell Death) 
Regulates cell apoptosis, 
forming heterodimers 
with BCL-xL and BCL-2 
and reversing their death 
repressor activity. 
Forward: 
5’GAGGATGA
GTGACGAGT
TTGTG3’ 
Reverse: 
5’CGGGATGT
GGAGCGAAG
G3’ 
107,1% 59˚C 
  
4.3. Real-Time PCR 
For the study on mRNA expression, a Real-Time PCR using the iQ5 Multicolor Real-Time 
PCR Detection System (Bio-Rad) was performed in a final reaction volume of 20 µL with 
10 µL iQ supermix, 0.4 µL forward and reverse primer (given the final concentration of 
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200 nM each), 1 µL 1x iQ SYBR Green Supermix (Bio-Rad), 2 µL cDNA sample (1:10 
diluted) and 7.2 µL sterile water. The samples were run with a duplicate negative control 
(NTC) to assure the absence of contaminations, and with a duplicate of standard cDNA 
pool from RKO cells without treatment (1:10 diluted).  
Standard curves were analysed from the diluted cDNA pool and the resulting amplification 
efficiency of the primers should be between 86.4% and 108.2%. The view of the melt 
curve from the RT-PCR analysis monitored the specificity of the performed reaction. 
For the correct RT-PCR mRNA expression in the Bio-Rad iQ5 software, the step point 
should be on the “annealing temperature” of each gene, the analysis mode is “PCR base 
line subtracted” and the baseline threshold was selected at the value of 80. 
To perform the gene normalization in a previous work (81) was used the NormFinder 
software. With the results obtained was selected genes RPL8 and HPRT1. 
 
5. Proteomic Analysis 
The proteomic analysis was performed with the purpose of knowing the main differences 
in protein expression regarding the effect of cyanobacterial fraction in the selected cell 
line. 
5.1. Protein extraction from cells after exposure to the compound 
E13010 F 5.4 and quantification 
The protein extraction was performed by adding to the cell pellet a volume of 
solubilisation buffer (SB – Table 6) at a ratio of 80 µL to 15 mg of cell biomass. The cell 
line RKO proteins were extracted 2x on vortexing, each 30 seconds followed by sonication 
and cell line HT-29 were extracted 2x on vortexing, each 30 seconds. The homogenization 
process took 1 hour in the ice for RKO and 30 minutes for HT-29 and then the homogenate 
was centrifuged at 16,000 g, for 20 minutes, at 4 ˚C. The supernatant was collected and 
proteins were quantified using the Bradford method (Bradford, 1976). The protein samples 
were stored at -80 ˚C.  
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Table 6 Solubilisation buffer. 
Urea (7 M) 4.2 g 
Thiourea (2 M) 1.52 g 
CHAPS (4%, w/v) 0.4 g 
Dithiothreitol (DTT) (65 mM) 0.1 g 
Ampholytes (0.8%, v/v, pH 4-7) 8 µL 
Ultra-pure water 2 mL 
TOTAL VOLUME 10 L 
 
5.2. Two-dimensional Electrophoresis (2DGE) 
The proteins were separated by two-dimensional electrophoresis (2DGE) that separates 
proteins by their isoelectric point and molecular weight. Protein samples in the final 
concentrations indicated in Appendix 6, Table 19 were diluted in 125 µL of solubilisation 
buffer (SB) with 1 µg bromophenol blue (BPB) and centrifuged at 10 rcf for 10 minutes. 
Then, the protein samples were loaded in 11 cm, pH 3-10 IEF gel strips (Bio-Rad) being 
part of the acrylamide gel contact with the sample, applying 3 mL of mineral oil on top of 
the strip. The support was then transferred to the voltmeter (Bio-Rad Protean IEF Cell) and 
proteins separated by isoelectric focusing (IEF) with the following program: 
 Gel rehydration 12 hours at 50 V;  
 Step 1 – 250 V for 15 minutes; 
 Step 2 – 2 hours voltage gradient to 4000 V (linear ramp); 
 Step 3 – 4000 V until achieving 20000 V/h (linear ramp). 
At the end of the first dimension, the IEF gel strips were stored at -20 ˚C until performing 
the second dimension, SDS-PAGE. Before the second dimension electrophoresis IEF gel 
strips need to be equilibrated using two solutions (Table 7), Equilibration Buffer 1 with 
12.5 mg/mL dithiothreitol (DTT) and Equilibration Buffer 2 with 25 mg/mL 
iodoacetamide in urea (6 M), glycerol (30%, v/v), SDS (2%, w/v), both during 15 minutes 
with slow agitation and with 2 mL of each solution to an IEF strip. 
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Table 7 Equilibration Solution (EqS). 
Tris-HCl (1,5 M, pH 8,8 stock solution) 10 mL  
Urea (6 M) 72.1 g 
Glycerol (29.3 %, v/v) 69 mL 
SDS (2%, w/v) 4 g 
Bromophenol blue 4 mg 
TOTAL VOLUME 200 mL (with H2O) 
Equilibration buffer 1 Add 100 mg DTT to 10 mL of EqS 
Equilibration buffer 2 Add 250 mg of iodoacetamide to 10 mL EqS 
 
The second dimension consisted of polyacrylamide gel electrophoresis 12.5% (w/v) under 
denaturing conditions (SDS-PAGE). Electrophoresis was performed in the power supply 
system Hoefer PS600 coupled vertical unit electrophoresis SE900 (Hoefer, EUA, 
Massachusetts). The electrophoresis system enables the six gels run at the same time. For 
the polymerisation were required a volume of 400 mL. Gels were prepared as follows:      
166.7 mL acrylamide 30% (w/v) (Bio-Rad, USA, California); 124,8 mL destilled water; 
100 mL gel buffer (1,5 M Tris-HCl, pH 8,8); 4 mL 10% SDS (Sodium Dodecyl Sulfate) 
(Sigma-Aldrich); 4mL 10 % APS (Ammonium Persulphate) (Sigma-Aldrich) and 0.55 mL 
10% TEMED (N, N, N’, N’ - tetramethylehylendiamine) (Bio-Rad). After equilibration of 
isoelectric focusing, strips were applied on these gels alongside molecular weight 
molecular markers (Bio-Rad). Electrophoresis of the second dimension was done with 
constant amperage of 480 mA for a period about 6 hours.   
5.3. Fixation and staining of polyacrylamide gels 
After the electrophoresis run, each of the polyacrylamide gels were fixed for 24h using a 
mixture of 2 L distilled water, 800 mL methanol (40%, v/v) (Merck, USA, New Jersey) 
and 200 mL acetic acid (10%, v/v) (Panreac, Spain, Barcelona), using 200 mL per gel.   
Gels were stained according to the protocol described in the article of Neuhoff  V. (75). 
For Coomassie Blue staining 4 volumes of the staining solution were mixed with 1 volume 
of methanol, with constant agitation using 200 mL each gel. Solution A is made up of      
10 mL ortho-phosphoric acid (2%, w/v) (Merck), 50 g ammonium sulphate (10% w/v) 
(Fisher Scientific, USA, Massachusetts) and 500 mL distilled water. Solution B contains 
0.5 g Coomassie Blue G250 (5%, w/v) (Sigma-Aldrich) and 10 mL distilled water. Before 
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application of the staining mixture, each gel was washed with 100 mL of mili Q water 
during 10 minutes. Each gel was then stained under constant agitation overnight. In the end 
of the staining procedure, gels were extensively washed with mili Q water to remove the 
colloidal particles, 5x for 10 minutes, until the water stays transparent and is not blue 
anymore, and stored in the storage solution with 400 g ammonium sulphate (20%, w/v) 
(Fisher Scientific, USA, Massachusetts) and 2 L of distilled water at room temperature. 
5.4. Gel Image Acquisition and Protein Expression Analysis 
Digital image from the gels were obtaining using the software Quantity One (Bio-Rad) 
associated with the densitometer GS-800 (Bio-Rad), reproducing the sensitivity parameters 
for all the gel images. The images obtained were analysed for differentially expressed spots 
using software PDQuest Advanced 8.0 (Bio-Rad) and consisted of: detect spots on the gels; 
align gels; determine the relative intensity of each spot.  The spot detection and matching 
was manually revised in the software. When the protein expression was analysed, a master 
gel was created in the software, which contained all the spots detected in the 2DGE gel 
images. Software analysis allowed us to make quantitative and qualitative comparisons of 
spots between gels, calculate values of molecular weight and isoelectric points. The spot 
expression (presence/absence) and intensity variations were also analysed, by comparing 
each protein spot between all the gels in the experimental groups. The quantitative 
variations were statistically evaluated by the t-student and Mann-Whitney tests (p ≤ 0.05). 
This screening process was done for each gel control and treatments group, and has been 
analysed 4 replicate gels per group. In total of 16 gels were analysed for both cell lines (8 
for RKO and 8 for HT-29). 
5.5. Preparation of proteins samples for matrix-assisted laser 
desorption/ionization (MALDI) time-of-flight / time-of-flight 
(TOF/TOF) 
Matrix-assisted laser desorption/ionization (MALDI) time-of-flight/time-of-flight 
(TOF/TOF) high-resolution tandem mass spectrometer is used for protein identification. 
This instrument has high sensitivity for peptide analysis associated with MALDI and 
comprehensive fragmentation information provided by high-energy collision-induced 
dissociation (CID). 
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Subsequently the selection of spots with biological interest using the software PDQuest 
Advanced 8.0 (Bio-Rad), they were excised from the gels and washed the spots with 30 µL 
of ultra-pure water for 20 minutes at room temperature. Thereafter, water was removed by 
adding 30 µL of acetonitrile (ACN) 50% and incubated for 30 minutes at room 
temperature with stirring, to remove all coloration of the gel pieces. After complete 
discoloration of the gel pieces, ACN was removed and added 30 µL ACN 100% and 
remained at room temperature and stirred for 5 minutes and repeat the process for 30 
minutes. Afterword, the solvent was removed and the gel pieces dried overnight at room 
temperature. After being totally dried, was added 20 µL of trypsin at a concentration of   
6.7 ng/µL for 30 minutes on ice. Removal of trypsin and added 20 µL of ammonium 
bicarbonate (Sigma), digestion overnight at 37 ˚C, and storage of peptides at -20 ˚C. 
For application in MALDI-TOF/TOF plate, the samples were previously concentrated and 
desalted using micro columns 10 µL Pierce® C18 Tips (Thermo Scientific), using a micro 
column per sample. The columns were activated with 50% ACN with two cycles of 10 µL, 
then being equilibrated with trifluoroacetic acid (TFA) (Sigma-Aldrich), again two cycles 
of 10 µL. To bind the peptides to the column aspire and dispense 10 µL of the sample ten 
cycles. After the 10 cycles, dispense the volume sample back to the PCR tube. Wash the 
column with two cycles of 10 µL rinse solution (0.1% TFA in 5% ACN) and dispense to 
waste. Since the peptides are already bind to the column, the rinse solution should be 
distributed into individual PCR tubes (about 30 µL) for each sample to avoid 
contamination between samples. The peptides were eluted with the matrix for MALDI 
identification (100% ACN of 500 µL, 5% TFA of 20 µL, 7-8 mg of α-cyano-4-
hydroxycinnamic acid (Sigma) of 7 mg and distilled water of 480 µL). Separate 2.5 µL of 
the matrix to clean PCR tubes and pipette and dispense the solution until five times. 
Dispense 1.7 µL of peptide solution on the MALDI plate Opti-TOF™ 384 Well Insert (123 
x 81 mm) (Applied BioSystems) avoiding bubble formation that may affect the peptide 
crystallization on the plate. Final identification by MALDI-TOF/TOF was acquired as 
service from the IPATIMUP (Institute of Molecular Pathology and Immunology of the 
University of Porto), Porto.  
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IV. Results 
1. Cyanobacterial Fractioning to pure compound 
During eight months the cyanobacteria strain LEGE 06099 was cultured in around   
100 L and was obtained 28.3 g of lyophilized biomass from which the compound was 
extracted. The ten fractions obtained during fractionation were analysed by Nuclear 
Magnetic Resonance spectroscopy (Appendix 1, Figure 19 – 27). As expected from 
previous work (85) the compound of interest was located in the fraction F (Figure 5), 
singlets at δ6:50 and δ6:35. 
 
Figure 5 Fraction F. 
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1.1. Thin Layer Chromatography (TLC) 
The 75 sub-fraction were tested on twelve TLC plates (Appendix 2, Figures 28 – 39). The 
individual compounds appear as spots and run different distances. The compounds are 
grouped as it travels over the same distance. Therefore, there was obtained seven groups, 
as shown in Table 8. 
Table 8 Sub-fractions have been grouped. 
Sub-Fraction Group 
1 – 4 --- 
5 – 6 1 
7 2 
8 3 
9 – 10 4 
11 – 24 5 
25 – 30 6 
31 – 75 7 
 
2. Cell Culture and Cytotoxicity Assays 
2.1. Exposure to cyanobacterial compound E13010 F 5.4 and 
cytotoxicity assays 
For the evaluation of the cytotoxicity induced by the compound E13010 F 5.4 four tumour 
cell lines (HT-29, RKO, MG-63 and T47D) and concentration range (30 µg/mL, 3 µg/mL, 
0.3 µg/mL, 0.03 µg/mL and 0.003 µg/mL) were assayed in 96-well plates, at a 
concentration of 3.3x10
4
 cell/mL, with two exposure times, 24 and 48 hours (Appendix 3, 
Figures 40 – 43), but only the tumour cell line RKO and HT-29 at a concentration 30 
µg/mL was selected for the following mRNA expression and proteomic analyses.  
The MTT assay is a fast colorimetric method used to measure cell proliferation and to 
screen for anticancer drugs. The method is based on reduction of the tetrazolium salt, MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by actively growing cells 
to purple formazan crystals, which accumulate in endosomal and/or lysosomal 
compartments, being later transported out of the cell by exocytosis. Due to the fact that this 
a fundamental mechanism of living cells, this assay has been frequently used to determine 
cellular viability (83). The MTT assay was used to evaluate the effect of the compound 
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E13010 F 5.4 on the inhibition of cellular proliferation of human tumour cell lines and 
cytotoxicity. 
The results regarding cell viability of the RKO and HT-29 tumours cells lines exposed of 
the compound E13010 F 5.4 at a concentration of 30 µg/mL in 24-well plates, at a 
concentration of 1x10
6
 cell/mL and for 24 hours are presented in Figures 6 and 7. The 
negative control consisted of growth medium with 1% DMSO and a positive control 20% 
DMSO with growth medium. The reduction in cell viability of both tumour lines proves 
the cytotoxicity of the compound E13010 F 5.4. The difference in cell concentration in 24 
and 96-well plates is due to the fact that did not have enough cells and therefore results in 
difference from the previous work (80). 
 
Figure 6 Cell viability from compound E13010 F 5.4 of the cyanobacterial strain LEGE06099, in the RKO 
tumour cell line, at a concentration 30 µg/mL, with exposure time of 24 hours at 1x10
6
 cells per well. The 
negative control corresponds to 1% DMSO (90 µL) and the positive control to 20% DMSO (400 µL). 
 
Figure 7 Cell viability from compound E13010 F 5.4 of the cyanobacterial strain LEGE06099, in the RKO 
tumour cell line, at a concentration 30 µg/mL, with exposure time of 24 hours at 1x10
6
 cells per well. The 
negative control corresponds to 1% DMSO (90 µL) and the positive control to 20% DMSO (400 µL). 
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3. Gene Expression Analysis 
3.1. RNA isolation and cDNA 
After the process with Total RNA Isolation (Macherey-Nagel) kit, RNA was quantified 
with the Qubit® Fluorometer (Invitrogen) (results from quantification in Appendix 4 
Table 11). After quantification, the quality of RNA was confirmed with agarose gel 
electrophoresis as presented in Figures 8 and 9. RNA quality was considered as 
reasonably, since sharp bands were obtained for 28S and 18S rRNA. The absence of the 
28S:18S rRNA ratio of 2:1 was observed, but regarded as uncritical since no signs of 
genomic contamination or RNA degradation were present. 
 
 
Figure 8 Agarose gel electrophoresis for the samples treated with tumour RKO cell line, replicate 1 treated 
with compound and replicate 1 for negative control and samples treated tumour HT-29 cell line, replicate 3 
treated with compound and replicate 3 for negative control. 
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Figure 9 Agarose gel electrophoresis for the samples treated with tumour RKO cell line, replicate 2, 3, 4, 5, 6 
treated with compound and replicate 2, 3, 4, 5, 6  for negative control and samples treated tumour HT-29 cell 
line, replicate 4, 5, 6 treated with compound and replicate 4, 5, 6 for negative control. 
 
3.2. Real-Time PCR 
Effects of the compound on cells were analysed by mRNA expression of genes involved in 
molecular mechanisms of the cell. The target genes selected for this analysis were RPL8, 
HPRT1, VDAC, SHMT2, CCNE, CCNB1, P21CIP, BCL-2 and BAD, comprising genes 
from the cell cycle regulation and apoptosis. The RPL8 and HPRT1 genes were used as 
reference genes in accordance to a previous study of our working group (81). The mRNA 
expression was analysed between two different groups: a control group were RKO and 
HT-29 cells were exposed to 1% DMSO; a treatment group where RKO and HT-29 cells 
were exposed to the cyanobacterial compound E13010 F 5.4. The results of Real-Time 
PCR are on the Appendix 5, Table 12 – 18. 
After obtaining these data, we used the GraphPad Prism® software. The program used the 
Kolmogorov – Smirnov test, the Student T – test and the Mann-Whitney test. The test 
Kolmogorov – Smirnov can be used to evaluate two hypotheses: the data follow a normal 
distribution or the data does not follow a normal distribution. The Student T – test is 
parametric and requires a normal distribution. It is used on two independent samples. The 
Mann-Whitney test (Wilcoxon rank-sum test) or U – test is indicated for comparison of 
two unpaired groups to see if they belong or not to the same population. The U – test is 
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non-parametric and is used in independent random samples and testing the equality of 
medians. The U values evaluating the degree of entanglement of the data of the two groups 
after ordering. The greater separation of the data set indicates that the samples are 
different, rejecting the hypothesis of equality of medians.  
Analysis of mRNA expression in cell cycle genes, CCNB1, CCNE and P21CIP  in  the 
RKO cell line indicated that there are no significate changes in CCNB1 and CCNE genes 
expression, but there are significant changes in P21CIP gene (p < 0.05 significant value) 
(Figure 10). 
  
Figure 10 Relative mRNA expression from selected cell cycle genes CCNB1, CCNE, P21CIP treated with 
RKO cell lines (* p < 0.05 significant value). 
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In the apoptotic genes BCL-2 and BAD and also in the RKO cell line, there was only a 
small change in the gene BAD (p=0.087) exposed to the cyanobacterial compound 
(Figure11). The change does not have significant value, but indicates a tendency. 
 
Figure 11 Relative mRNA expression from selected apoptosis genes, BCL-2 (anti-apoptotic) and BAD (pro-
apoptotic) treated with RKO cell lines. 
In other genes related to cancer (VDAC and SHMT2) of cell line RKO, no changes were 
observed between the control group and the group exposed to the cyanobacterial 
compound (Figure 12). 
 
Figure 12 Relative mRNA expression from other cancer-related genes, VDAC and SHMT2 treated with 
RKO cell lines. 
Regarding the analysis of mRNA expression of the genes of cell line HT-29, no significant 
changes were observed both in cell cycle genes (Figure 13), as in apoptotic genes (Figure 
14). However, in other cancer-related genes, including the gene VDAC (Figure 15) mRNA 
expression seemed increased (p=0.114), but the value was not statistically significant. This 
may be due to the fact that instead of 6 replicas were used only 4 since due to low yield in 
protein extraction two replicates from genomics were dedicated to proteomics. 
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Figure 13 Relative mRNA expression from selected cell cycle genes CCNB1, CCNE, P21CIP treated with 
HT-29 cell lines. 
 
Figure 14 Relative mRNA expression from selected apoptosis genes, BCL-2 (anti-apoptotic) and BAD (pro-
apoptotic) treated with HT-29 cell lines. 
 
Figure 15 Relative mRNA expression from other cancer-related genes, VDAC and SHMT2 treated with HT-
29 cell lines. 
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4. Proteomic Analysis 
4.1. Protein extraction and quantification 
The RKO and HT-29 cell lines were exposed to cyanobacteria compound, at a 
concentration of 30 µg/ mL and negative control with 1% DMSO. After 24 hours of 
exposure, proteins were extraction was performed as described in the materials and 
methods section. The Appendix 6, Table 19 indicates the concentration of protein extracted 
from each sample. 
4.2. Two-dimensional Electrophoresis (2DGE) 
Each protein extract was subjected to two-dimensional electrophoresis with a first phase 
isoelectric focusing followed by SDS-PAGE, the cells proteome to be resolved between 
isoelectric points 3 – 10. We performed a polyacrylamide gel (12.5%) for each protein 
extract (see protein concentration in Appendix 6, table 19) from each cell line and the 
respective control and treatment groups, in Figure 16 this is an example of a 
polyacrylamide gel. 
 
Figure 16 Polyacrylamide gel (12.5%) performed for the RKO (A) and HT-29 (B) cell line exposed at a 
concentration of 30 µg/mL of compound E13010 F 5.4.. The molecular weight of the gels between 202 and 6 
KDa. 
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The polyacrylamide gels, a total of 16 (4 for each study group) were analysed by PDQuest 
(BioRad) software. Were identified 220 gel spots by the RKO cell line and 136 gel spots in 
the HT-29 cell line. The 95% confidence level for the Student t-test was used to identify 
differentially expressed spots between control and treatment groups yielding a total of 35 
spots (see Appendix 7, Table 20) for cell line RKO and 26 spots (see Appendix 7, Table 
21) for cell line HT-29. 
In Figure 17, polyacrylamide gels (12.5%) are shown obtained for the cell line RKO 
treatment group exposed to 30 µg/mL of compound E13010 F 5.4 and negative control 
group with 1% DMSO. 
 
Figure 17 Polyacrylamide gels (12.5%) for the RKO cell line treatment group exposed to 30 µg/mL of 
compound E13010 F 5.4 and negative control (A – Replicate 1 treated with compound, B – Replicate 2 
treated with compound, C – Replicate 3 treated with compound, D – Replicate 1 for negative control) 
indicating the relative position of spots identified by the PDQuest software, using the t-test with a confidence 
level of 95%. 
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In Figure 18, the polyacrylamide gels (12.5%) are shown obtained for the cell line HT-29 
treatment group exposed to 30 µg/mL of compound E13010 F 5.4 and negative control 
group with 1% DMSO. 
 
Figure 18 Polyacrylamide gels (12.5%) for the HT-29 cell line treatment group exposed to 30 µg/mL of 
compound E13010 F 5.4 and negative control (A – Replicate 1 treated with compound, B – Replicate 2 
treated with compound, C – Replicate 3 treated with compound, D – Replicate 1 for negative control), 
indicating the relative position of spots identified by the PDQuest software, using the t-test with a confidence 
level of 95%. 
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4.3. Preparation of peptides for identification in matrix-assisted 
laser desorption ionization (MALDI) time-of-flight / time-of-
flight (TOF/TOF) 
From the 35 differentially expressed spots of cell line RKO identified by the PDQuest 
software, 16 spots were analysed so far by MALDI-TOF/TOF. Regarding the 26 spots of 
cell line HT-29, 5 spots were analysed so far by MALDI-TOF/TOF (Table 9).  
Protein score is -10*Log(P), where P is the probability that the observed match is a random 
event. Protein scores greater than 65 are significant (p<0.05) and are derived from ions 
scores as a non-probabilistic basis for ranking protein hits. 
 
 
Table 9 Spots analysed of RKO and HT-29 cell line. 
Cell line Spots Cell line Spots 
RKO 
2303 
HT-29 
202 
2707 2411 
3303 2605 
3313 4407 
3405 6101 
3517   
3520   
3831   
3832   
3844  
4303   
4510   
5505   
6304   
7102   
8111   
 
Only three spots were identified with statistical confidence, the spot 2707 and 6304 of 
RKO cell line and spot 2411 of HT-29 cell line. We conducted sequencing of the 25 
peptide peaks having a relative noise signal sample and identified only two very similar 
proteins (Table 10). 
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Table 10 Identification of proteins by MALDI-TOF / TOF. For each protein is indicated name and accession 
number thereof by comparison with the UniProt database (84). 
Spot Accession Protein name Protein score Function 
2707 
P11021 
78 kDa glucose-
regulated protein 
(Homo sapiens) 
680 Facilitate the 
assembly 
multimeric proteins 
complex inside the 
endoplasmic 
reticulum. 
B4DEF7 
cDNA FLJ60062, 
highly similar to 78 
kDa glucose-regulated 
protein (Homo 
sapiens) 
244 
6304 P06733 
Alpha-enolase (Homo 
sapiens) 
264 
Stimulates 
immunoglobulin 
production and 
may be a tumour 
suppressor. 
2411 B4DW52 
cDNA FLJ55253, 
highly similar to Actin, 
cytoplasmic 1(Homo 
sapiens) 
198 ATP binding.  
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V. Discussion  
The compound E13010 F 5.4 used in this work was previously isolated from the marine 
cyanobacteria strain Synechocystis salina LEGE 06099 (75). In order to get more biomass 
for new isolation of the compound the cyanobacteria strain was cultured in large scale. All 
the fractionating procedure, NMR analysis and TLC analysis were performed during this 
thesis. 
Analysing all the results from the cytotoxicity assays, it was confirmed that cyanobacterial 
compound E13010 F 5.4 induced cytotoxicity that was more pronounced and dependent on 
the concentration on the cancer cell lines RKO and HT-29. Considering these results and 
due to the small amount of compound available only RKO and HT-29 cells lines were 
selected for the mRNA expression and proteomic analysis. 
Overall, the analysis of mRNA expression indicated a significant variation compared to 
control for P21CIP, while a tendency of variation was present for BAD, BCL-2, CCNB1 
and VDAC, however responses were different between both cell lines.  
Analysis of mRNA expression genes of the RKO cells revealed a significant decrease of 
the P21CIP gene (p < 0.05). The P21CIP is a cell cycle regulator, which is involved in the 
anti-proliferation of cells by inhibiting cell cycle progression at the G1 to S phase (85, 86). 
The cyclin-dependent kinase inhibitor p21 promotes cell cycle arrest in response to many 
stimuli and, in many tumours, the increase of P21CIP resulted in a decreased ability of 
cells to divide. It also acts as a major effector of multiple tumour suppressor pathways to 
promoting anti-proliferative activity. The induction of P21CIP is a good indicator of 
growth arrest in colorectal cancer cells (85). Although the cyclin-dependent kinase 
inhibitor p21 was originally considered to be a tumor-suppressor it has been suggested that 
p21 may also act as an oncogene because it often inhibits apoptosis (80). Considering our 
results however the observed decrease of P21CIP mRNA expression is probably not 
related to the described effects above, but would indicate an increased proliferation, a 
decreased tumour suppression or reduction of the oncogene. At the moment, it is not clear 
how the observed effects connect to the induced cytotoxicity of the compound in the RKO 
cancer cell line.  
Regarding the pro-apoptotic gene BAD, a non-significant decrease was observed in the 
RKO cell line (p=0.087) exposed to compound. In the literature it was demonstrated that 
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the relative levels of BCL-2 and BAD contribute to determine the drug resistance of colon 
tumour cells (87). The function of BAD is to regulate the phosphorylation state that 
modulates its protein–protein interactions and subcellular localization. Protein kinases 
phosphorylate BAD on serine residues. Phosphorylation at these sites enables BAD to bind 
with proteins and inhibits the binding of BAD with BCL-2, resulting in the inhibition of 
apoptosis. It is believed that apoptosis of cells is important in the pathogenesis of tumours 
(88). BCL-2 is an anti-apoptotic regulatory protein, but it also act as an inhibitor of 
proliferation. The function of BCL-2 in carcinogenesis is controversial, as the anti-
apoptotic effect may be oncogenic while the anti-proliferative effect appears tumour-
suppressive. This functions may be specific of tissue, so the prognostic implication of 
BCL-2 expression depends on cancer type (89). A decrease of the mRNA expression of 
pro-apoptotic gene BAD would indicate that maybe cells do not enter into apoptosis. This 
finding may also be supported by the increase in the expression of the gene CCNB1 since 
this gene encodes for cyclin B1, which is essential for the control of the cell cycle at the 
G2/M transition. The results may suggest a response of cells to fight against induced 
cytotoxicity. In RKO cell line, the gene CCNB1 is up-regulated, however, not statistically 
significant, which may indicate that cells proliferate and enter into the G2/M phase of the 
cell cycle. CCNB1 is a member of cyclin family involved in the quality control step of 
mitosis. It has been demonstrated that CCNB1 is involved in checkpoint control, whose 
dysfunction is an early event in carcinogenesis, and deregulated expression is observed in 
various human cancers like breast cancer, cervical cancer, lung cancer, esophageal 
squamous cell carcinoma, and melanoma (90). CCNB1 is overexpressed in the most 
human colorectal cancer tissues compared with the matched adjacent non tumours tissues. 
The literature suggested that CCNB1 promotes the proliferation of colorectal cancer cells 
in vitro and carcinogenesis in vivo, its mean CCNB1 exerts a growth-promoting function in 
human colorectal cancer. In short, it is believed that CCNB1 have an oncogenic role in 
colorectal cancer. CCNB1 is activated by checkpoint kinase 1 overexpression and 
inhibition of CCNB1 induces cell cycle arrest in different colorectal cancer cell lines 
through modulating the expression of G2/M cell cycle regulators. Suppression of CCNB1 
induces apoptosis in a fewest colorectal cancer cells (90).  
Regarding the analysis of mRNA expression of the genes of HT-29 cell line, we were 
faced with a difficulty that there were less replicates then in the RKO cell line (see chapter 
IV, section 3.2. Real-Time PCR). In this cell line, however, the genes CCNBI, P21CIP, 
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BCL-2 and VDAC (see chapter IV, section 4, Figure 13 – 15) showed a tendency to be 
increased although the values did not reach statistical significance. 
As mentioned previously the gene CCNB1 is involved in mitosis checkpoint control, 
whose dysfunction is an early event in carcinogenesis, and deregulated expression is 
observed in various human cancers but the role of this gene is still unclear in colorectal 
cancer (90). The P21Cip is a cell cycle regulator, which is involved in the anti-proliferation 
of cells by inhibiting cell cycle progression at the G1 to S phase and is a good indicator of 
growth arrest in colorectal cancer cells (85, 86). BCL-2 is an anti-apoptotic regulatory 
protein, but it also an inhibitor of proliferation. Nevertheless, the function of BCL-2 in 
carcinogenesis is not clear (89). The voltage dependent anion channel (VDAC) is a class of 
porin ion channels located on the outer membrane of mitochondria. VDACs have an 
important role in mitochondria-mediated apoptosis. There is evidence that VDAC is 
involved in tumour progression.  It was demonstrated that VDAC is up-regulated in tumour 
tissue in lung, breast, colon, liver, pancreatic, and thyroid cancers (91). In these case genes 
with functions in cell proliferation seem to be more expressed which may indicate an effort 
of cells to proliferate. It is assumed that a higher number of replicates would have resulted 
in significant alterations of these genes.  
The analysis of the proteome by 2DGE resulted in differentially expressed spots for the 
RKO cell line and in differentially expressed spots for the HT-29 cell line. Apparently, the 
gel pictures of the proteomes of both cell lines were different, which indicated that major 
expressed proteins might be different considering their pH values and their molecular 
weight. The analysis of the altered proteins in response to the exposure to the compound 
already indicated that different responses were present in both selected cancer cell lines. 
Differentially expressed spots had a different profile regarding their molecular weight and 
pH, as separated in the 2DGE. In order to identify those spots, we forwarded them to 
peptide identification by MALDI-TOF/TOF. Of the 21 spots analysed, only four proteins 
could be identified with statistical significance, spot 2707, the 78 kDa glucose-regulated 
protein (GRP78), cDNA FLJ60062, highly similar to 78 kDa glucose-regulated protein (in 
RKO); spot 6304, Alpha-enolase (EnoA; in RKO); spot 2411, cDNA FLJ55253, highly 
similar to Actin, cytoplasmic 1 (in HT29). Both GRP78 and EnoA were decreased in RKO 
cell line, while actin was increased in HT-29 (Appendix 7).  
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Typically, human colon cancer cells have hypoglycemic and hypoxic centres due to 
incomplete vasculature, which results in an increased glucose uptake, and glycolysis as an 
important energy source (92). GRP78 is significantly increased in colon tumours compared 
to normal mucosa, suggesting that up-regulation of GRP78 can be a marker of malignant 
transformation, but is not a useful prognostic marker (87). 78 kDa glucose-regulated 
protein is a member of the 70 kDa heat shock family of stress proteins, resident in the 
endoplasmic reticulum, and participate in assembly and integral membrane proteins (87). 
This protein has been implicated in the development of tumorigenicity, drug resistance, 
and cytotoxic immunology. The cellular changes in solid tumours in vivo, such as hypoxia, 
glucose deprivation and alterations in calcium flux may result in an accumulation of 
unfolded proteins and/or deformation of the lumen of the endoplasmic reticulum (ER), and 
may impair the function of the ER-Golgi network (88, 89). Angiogenesis regulates the 
degradation of extracellular basement membrane of the original vessel proliferation and 
formation of new capillaries (90). The glucose-regulated proteins (GRP) are a group of 
proteins, whose synthesis was increased in the cells deprived of glucose (87). GRP78 is a 
major pro-angiogenic chaperone protein, mainly found in the ER lumen, and promotes 
tumour proliferation, survival, angiogenesis and resistance of chemotherapy (90). GRP78 
protects tumour cells against the toxic effects of anticancer agents in vitro, and 
concordantly the induction of GRP78 can protect tumour cells in vivo. GRP78 levels are 
high in various cancer cell lines, solid tumours and human cancers biopsies, and appear to 
correlate with malignancy. Furthermore, GRP78 induction protects cancer cells from 
immune surveillance, while suppression of GRP78 improved apoptosis-inhibited tumour 
growth and increased the cytotoxicity of chronically hypoxic cells.  
In the line of the above described knowledge, a decreased presence of the GRP78 protein 
as observed in this study in the RKO cell line could be involved in the mechanism leading 
to a shortage in glucose supply, and reduced proliferation and survival of colon cancer 
cells (93).  
Another protein identified by MALDI-TOF/TOF was alpha-enolase. Enolase (ENOA; 2-
phospho-D-glycerate hydrolase) is a very ubiquitous conserved cytosolic metalloenzyme 
with a molecular weight of 48 kDa. It catalyzes the dehydration of 2-phospho-D-glycerate 
to phosphoenolpyruvate in the glycolytic pathway. It exists in three different isoforms, 
alpha, beta, and gamma based on three independent loci (91). Alpha-enolase was present in 
almost all adult tissues, beta-enolase was expressed in muscle tissues, and gamma-enolase 
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was found in neurons and neuroendocrine cells. EnoA was known as a very important 
glycolytic enzyme, responsible for catalysing the dehydration of 2-phosphoglycerate to 
phosphoenolpyruvate in the final steps of glycolysis and been implicated in many other 
biological and physiological processes (92). EnoA has been detected on the surface of 
vascular endothelium, various cell types including monocytes, macrophages, B cells and T 
cells and is recognized as a plasminogen receptor. EnoA as a tumour associated antigen 
pancreatic ductal adenocarcinoma and a moonlighting protein that works both as a 
glycolytic enzyme and as a membrane plasminogen receptor, thus promoting tumour 
proliferation (93). Furthermore, EnoA is believed to have the function of a tumour 
suppressor. In tumour cells, is up regulated and supports anaerobic proliferation (94). In 
our study, EnoA is significantly decreased and could be involved in a decreased rate of 
glycolysis, where it catalyses the final step. Interestingly, both altered and identified 
proteins in the RKO cell line exposed to compound E13010 F 5.4 indicate alterations in the 
glycolysis, which may lead to a shortage in energy supply.  
The third identified protein was cDNA FLJ55253, highly similar to Actin, cytoplasmic 1 or 
Beta-actin. In all eukaryotic cells, actin family involves highly conservative proteins. Actin 
has different functions in the cell, including cell motility, contractile ring formation during 
cytokinesis, conservation of cell shape, signal transduction, cell adhesion, transcription and 
muscle contraction. In vertebrates, six actin isoforms are expressed. They were classified 
according to the isoelectric point and primary tissue or cellular location and comprise β- 
and γ-cytoplasmic, α-skeletal, α-cardiac, and α- and γ-smooth muscle isoactins. 
Mammalian erythrocytes comprehend only β-actin. Actin isoforms are products of separate 
genes, but there is a similarity in their nucleotide sequences that result in the primary 
structure of the protein. The differences between the actin isoform are more variable in the 
N-terminal region of actin molecule. Changes in the levels of actin isoforms in cells are 
often associated with pathological processes. It has been demonstrated that abnormal levels 
of β- and γ-actins was present in many tumour types like chemically induced melanoma, 
hepatoma, lymphoma, and breast cancer. Cytoplasmic β-actin appears to be over-expressed 
in many tumours, especially actively moving cancers cells. This isoform level was also 
significantly increased in some cases, highly invasive variants of colon cancer cells, 
MDCK cells transformed by Moloney sarcoma virus or melanoma cells T1C1  (95). 
Primary canonical pathway analyses identified actin-cytoskeleton pathway to be of great 
relevance, and expressively disrupted in the progression of normal colonic mucosa. The 
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actin-cytoskeleton pathway is a very important component in the movement of cells, and it 
is supposed to represent the backbone of cells that allow cell migration and mobility within 
the body. The actin-cytoskeleton pathway has already connected in the development and 
pathogenesis of invasive metastatic sporadic CRC. New studies have suggested that actin-
cytoskeleton pathway can be involved in the metastasis sporadic CRC through cytoskeletal 
proteins such as Fascin-1. The importance of disturbance of the actin-cytoskeleton pathway 
in the CRC is very interesting, especially since the detection of this deregulated pathway 
can provide a new screening and therapeutic target (96).   
Problems were met in the identification of peptide peaks due to the appearance of strong 
contamination peaks during the analysis. A re-identification of the spots is thereby 
necessary, after elimination of the unknown source of contamination. Since bacterial and 
fungal contamination could be excluded by the proteome analysis, currently plastic 
polymers are the main suspected contamination source. Therefore, the main interpretation 
of proteomic results has to be delayed until positive identification of differentially 
expressed spots by MALDI-TOF/TOF.  
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VI. Conclusion 
In this work we aim to infer about the potential of a marine cyanobacteria compound as an 
anticancer agent. By analysing the expression of genes involved in cell cycle and apoptosis 
and by applying a proteomic approach we aimed to reveal molecular and biochemical 
mechanisms involved in its cytotoxicity in cancer cell lines. In this analysis, the target gene 
with significant alteration was P21CIP, while a tendency of alteration was observed for 
BAD, BCL-2, CCNB1 and VDAC, though differences between the two cell lines were 
evident. The alteration of mRNA expression level of P21CIP, BAD and CCNB1 in RKO 
cells may indicate an increased proliferation, a decrease of pro-apoptotic protein level and 
entrance into the G2/M phase. However, reduced P21CIP level could be also indicative of 
reduced oncogene level. In HT-29 cell, no significant alterations were observed, but a 
similar tendency was present for induced cell proliferation (BCL-2, CCNB1). 
Nevertheless, increased VDAC mRNA expression may indicate higher permeability of 
mitochondria. Although results seem preliminary and need confirmation, it is clear that 
mechanisms are involved in cell death and proliferation, which may appear as counter-
regulation to the exposure.  
By peptide identification, three proteins have been identified: 78 kDa glucose-regulated 
protein; cDNA FLJ60062, highly similar to 78 kDa glucose-regulated protein; Alpha-
enolase; cDNA FLJ55253, highly similar to Actin, cytoplasmic 1. The apparent decrease 
of GRP78 and EnoA in RKO cells may indicate a reduction in glycolysis and thereby a 
shortage of important energy supply. In addition, the protein 78 kDa glucose-regulated has 
been implicated in the development of tumorigenicity, drug resistance, and cytotoxic 
immunology. Alpha-enolase is believed to have the function of tumour suppressor. The 
protein cDNA FLJ55253, highly similar to Actin, cytoplasmic 1 was increased in HT29 
cells, and alterations of the cytoskeleton is a known anti-cancer target. 
The repetition of assays during this project was limited by the small amount of the pure 
compound that was available. Further purification of the compound is ongoing, which will 
enable future studies that will deliver novel insights into the molecular mechanism of 
action of compound.   
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VIII. Appendix 
Appendix 1 – Nuclear Magnetic Resonance spectroscopy  
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Figure 20 Fraction B. 
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Figure 22 Fraction D. 
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Figure 26 Fraction Hx. 
 
Figure 27 Fraction I. 
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Appendix 2 – Thin Layer Chromatography 
 
 
Figure 28 Sub-Fraction 1 – 7. 
 
 
Figure 29 Sub-Fraction 8 – 15. 
  
 
Figure 30 Sub-Fraction 16 – 22. 
 
 
Figure 31 Sub-Fraction 23 – 28. 
  
 
Figure 32 Sub-Fraction 29 – 34. 
 
 
Figure 33 Sub-Fraction 35 – 41. 
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Figure 34 Sub-Fraction 42 – 47. 
 
 
Figure 35 Sub-Fraction 48 – 53. 
 
 
Figure 36 Sub-Fraction 54 – 59. 
 
 
Figure 37 Sub-Fraction 60 – 65. 
 
 
Figure 38 Sub-Fraction 66 – 72. 
 
 
Figure 39 Sub-Fraction 73 – 75. 
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Appendix 3 – Exposure to compound and cytotoxicity assays 
 
 
Figure 40 Cell viability from compound E13010 F 5.4 of the cyanobacterial strain LEGE06099, in the RKO 
tumour cell line, at a concentration 30 µg/mL, 3 µg/mL, 0.3 µg/mL, 0.03 µg/mL, 0.003 µg/mL, with 
exposure time of 24 and 48 hours at 3.3x10
4
 cells per well. The negative control corresponds to 1% DMSO 
(50 µL) and the positive control to 20% DMSO (100 µL).  
 
 
Figure 41 Cell viability from compound E13010 F 5.4 of the cyanobacterial strain LEGE06099, in the HT-
29 tumour cell line, at a concentration 30 µg/mL, 3 µg/mL, 0.3 µg/mL, 0.03 µg/mL, 0.003 µg/mL, with 
exposure time of 24 and 48 hours at 3.3x10
4
 cells per well. The negative control corresponds to 1% DMSO 
(12 µL) and the positive control to 20% DMSO (100 µL). 
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Figure 42 Cell viability from compound E13010 F 5.4 of the cyanobacterial strain LEGE06099, in the MG-
63 tumor cell line, at a concentration 30 µg/mL, 3 µg/mL, 0.3 µg/mL, 0.03 µg/mL, 0.003 µg/mL, with 
exposure time of 24 and 48 hours at 3.3x10
4
 cells per well. The negative control corresponds to 1% DMSO 
(50 µL) and the positive control to 20% DMSO (100 µL).  
 
 
Figure 43 Cell viability from the compound E13010 F 5.4 of the cyanobacterial strain LEGE06099, in the 
T47D tumour cell line, at a concentration 30 µg/mL, 3 µg/mL, 0.3 µg/mL, 0.03 µg/mL, 0.003 µg/mL, with 
exposure time of 24 and 48 hours at 3.3x10
4
 cells per well. The negative control corresponds to 1% DMSO 
(50 µL) and the positive control to 20% DMSO (100 µL).  
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Appendix 4 – Quantification of RNA 
 
Table 11 Quantification of RNA with the Qubit® Fluorometer (Invitrogen). 
Sample 
Concentration 
(µg/mL) 
RKO 
Replicate 1 treated with compound  59,8 
Replicate 2 treated with compound  522 
Replicate 3 treated with compound  394 
Replicate 4 treated with compound  415 
Replicate 5 treated with compound  257 
Replicate 6 treated with compound  467 
Replicate 1 for Control –  108 
Replicate 2 for Control –  459 
Replicate 3 for Control –  475 
Replicate 4 for Control –  523 
Replicate 5 for Control –  298 
Replicate 6 for Control –  296 
HT-29 
Replicate 3 treated with compound  104 
Replicate 4 treated with compound  365 
Replicate 5 treated with compound  168 
Replicate 6 treated with compound  219 
Replicate 3 for Control –  11 
Replicate 4 for Control –  194 
Replicate 5 for Control –  184 
Replicate 6 for Control –  296 
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Appendix 5 – Results of Real Time PCR 
 
Table 12 VDAC gene and geometric mean of RPL8 and HPRT1 genes. 
Sample Mean E(n) Standard deviation E(n) 
RKO 
Fraction F 2 1.9 0.37 
Fraction F 3 0.4 0.40 
Fraction F 4 0.8 0.75 
Fraction F 5 1.4 1.08 
Fraction F 6 1.0 0.28 
Control – 1 0.9 0.11 
Control – 2 0.7 0.04 
Control – 3 0.9 0.15 
Control – 4 1.8 0.60 
Control – 5 0.9 0.07 
Control – 6 1.4 0.82 
HT-29 
Fraction F 3 2.4 0.11 
Fraction F 4 1.9 0.08 
Fraction F 5 1.0 0.49 
Fraction F 6 2.1 1.03 
Control – 4 1.3 0.63 
Control – 5 0.9 0 
Control – 6 0.9 0.43 
 
Table 13 SHMT2 gene and geometric mean of RPL8 and HPRT1 genes. 
Sample Mean E(n) Standard deviation E(n) 
RKO 
Fraction F 2 1.7 0.85 
Fraction F 3 0.6 0.27 
Fraction F 4 1.2 0.46 
Fraction F 5 0.7 0.03 
Fraction F 6 1.6 1.41 
Control – 1 0.7 0.01 
Control – 2 1.2 0.29 
Control – 3 1.5 0.01 
Control – 4 2.4 1.54 
Control – 5 0.9 0 
Control – 6 0.4 0.17 
HT-29 
Fraction F 3 0.7 0.14 
Fraction F 4 2.5 0.34 
Fraction F 5 0.8 0 
Fraction F 6 2.2 1.44 
Control – 4 1.2 0.56 
Control – 5 1.2 0.14 
Control – 6 0.8 0.30 
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Table 14 CCNE gene and geometric mean of RPL8 and HPRT1 genes. 
Sample Mean E(n) Standard deviation E(n) 
RKO 
Fraction F 2 1.4 0.77 
Fraction F 3 0.5 0 
Fraction F 4 0.6 0.36 
Fraction F 5 0.8 0.52 
Fraction F 6 1.8 0.02 
Control – 1 1.0 0.03 
Control – 2 1.1 0.34 
Control – 3 1.4 0.41 
Control – 4 1.5 0.05 
Control – 5 0.9 0.18 
Control – 6 0.6 0.46 
HT-29 
Fraction F 3 1.0 0.27 
Fraction F 4 2.2 1.79 
Fraction F 5 1.0 0.92 
Fraction F 6 2.3 0.93 
Control – 4 1.0 0.37 
Control – 5 1.6 0.57 
Control – 6 0.7 0.47 
 
Table 15 CCNB1 gene and geometric mean of RPL8 and HPRT1 genes. 
Sample Mean E(n) Standard deviation E(n) 
RKO 
Fraction F 2 1.5 0.50 
Fraction F 3 2.8 1.40 
Fraction F 4 0.9 0.14 
Fraction F 5 1.6 0.24 
Fraction F 6 0.8 0.04 
Control – 1 0.8 0.07 
Control – 2 0.6 0.02 
Control – 3 0.9 0.03 
Control – 4 1.7 0.14 
Control – 5 1.2 0.15 
Control – 6 1.0 0.13 
HT-29 
Fraction F 3 2.5 1.29 
Fraction F 4 2.1 0.87 
Fraction F 5 1.4 0.64 
Fraction F 6 1.0 0.15 
Control – 4 1.6 0.49 
Control – 5 0.9 0.48 
Control – 6 1.0 0.75 
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Table 16 P21CIP gene and geometric mean of RPL8 and HPRT1 genes. 
Sample Mean E(n) Standard deviation E(n) 
RKO 
Fraction F 2 0.5 0.02 
Fraction F 3 0.3 0.08 
Fraction F 4 0.6 0.14 
Fraction F 5 0.1 0.10 
Fraction F 6 0.9 0.38 
Control – 1 1.0 0.02 
Control – 2 1.5 0.21 
Control – 3 1.4 0 
Control – 4 1.3 0.33 
Control – 5 1.1 0.06 
Control – 6 0.3 0.07 
HT-29 
Fraction F 3 0.8 0.08 
Fraction F 4 2.8 0.42 
Fraction F 5 1.7 0.11 
Fraction F 6 2.7 0.73 
Control – 4 0.9 0.22 
Control – 5 1.2 0.39 
Control – 6 1.1 0.60 
 
Table 17 BCL-2 gene and geometric mean of RPL8 and HPRT1 genes. 
Sample Mean E(n) Standard deviation E(n) 
RKO 
Fraction F 2 1.7 0.67 
Fraction F 3 0.9 0.37 
Fraction F 4 1.3 0.44 
Fraction F 5 1.5 0.71 
Fraction F 6 0.6 0.42 
Control – 1 0.5 0.23 
Control – 2 0.8 0.12 
Control – 3 0.9 0.43 
Control – 4 1.8 0.88 
Control – 5 1.2 0.16 
Control – 6 1.5 0.78 
HT-29 
Fraction F 3 1.1 0.22 
Fraction F 4 3.8 1.90 
Fraction F 5 2.7 1.86 
Fraction F 6 1.3 0.50 
Control – 4 0.9 0.49 
Control – 5 1.2 0.18 
Control – 6 1.2 0.86 
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Table 18 BAD gene and geometric mean of RPL8 and HPRT1 genes. 
Sample Mean E(n) Standard deviation E(n) 
RKO 
Fraction F 2 0.8 0.09 
Fraction F 3 0.6 0.02 
Fraction F 4 0.6 0.02 
Fraction F 5 0.2 0 
Fraction F 6 0.8 0.33 
Control – 1 0.8 0.26 
Control – 2 1.7 0.25 
Control – 3 2.2 0.13 
Control – 4 1.1 0.13 
Control – 5 1.1 0.06 
Control – 6 0.3 0.07 
HT-29 
Fraction F 3 0.5 0.01 
Fraction F 4 2.1 0.01 
Fraction F 5 0.8 0.09 
Fraction F 6 1.1 0.19 
Control – 4 1.2 0.26 
Control – 5 1.8 1.58 
Control – 6 0.7 0.49 
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Appendix 6 – Protein concentration 
 
Table 19 Protein concentration obtained from each samples of RKO and HT-29 cells line exposed to 
compound, according to the extraction protocol. 
Sample 
[Protein] 
µg/µL 
RKO 
Replicate 1 treated with compound  3.60 
Replicate 2 treated with compound  2.93 
Replicate 3 treated with compound  3.43 
Replicate 4 treated with compound  2.96 
Replicate 5 treated with compound  2.79 
Replicate 6 treated with compound  3.87 
Replicate 1 for Control –  5.97 
Replicate 2 for Control –  4.38 
Replicate 3 for Control –  4.47 
Replicate 4 for Control –  3.34 
Replicate 5 for Control –  3.03 
Replicate 6 for Control –  2.83 
HT-29 
Replicate 1 treated with compound  2.71 
Replicate 2 treated with compound  2.52 
Replicate 3 treated with compound  2.02 
Replicate 4 treated with compound  2.00 
Replicate 5 treated with compound  4.10 
Replicate 6 treated with compound  4.59 
Replicate 1 for Control –  4.42 
Replicate 2 for Control –  2.56 
Replicate 3 for Control –  2.29 
Replicate 4 for Control –  6.43 
Replicate 5 for Control –  1.40 
Replicate 6 for Control –  1.67 
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Appendix 7 – Relative intensity of the spots 
 
Table 20 Relative intensity of the spots differentially expressed in the cell line RKO, detected by PDQuest 
software based on t-test at 95% confidence. Representation for each spot, considering the control group and 
treatment, the average relative intensity and respective standard deviation. 
SSP 
Control – 
(Mean ± SD) 
Compound 
(Mean ± SD) 
1603 1151.9 ± 366.7 475.6 ± 356.3 
2303 17077.8 ± 3623.8 9011.9 ± 7516.3 
2707 16469.4 ± 2056.5 7328 ± 3872.3 
-++3303 1664.9 ± 445.1 710 ± 578.9 
3313 32.1 ± 0.0 204.4 ± 121.1 
3405 86.6 ± 49.5 544.1 ± 333.8 
3517 110.7 ± 132.9 393.1 ± 209.4 
3520 --- 738.3 ± 355.2 
3831 --- 137.5 ± 42 
3832 89.3 ± 62.8 277.3 ± 85.3 
3844 --- 164.3 ± 65.1 
4303 135.9 ± 103.6 396.8 ± 110.6 
4314 37 ± 34,3 615.9 ± 427.6 
4415 167 ± 102.0 354.3 ± 78.2 
4510 1831.5 ± 444.6 4014.9 ± 1692.1 
4518 310.1 ± 172.6 1802.4 ± 668 
4603 21.1 ± --- 427.1 ± 164.4 
4905 --- 158.9 ± 66.8 
4906 62.9 ± 1.1 102.5 ± 4.8 
5115 54.8 ± 14.2 14.5 ± 13.1 
5214 133.9 ± 56.7 341.2 ± 107.7 
5413 70.1 ± 43 160.9 ± 49.4 
5415 147.6 ± 49.5 362.2 ± 159.4 
5505 690.1 ± 178.3 1330.6 ± 403.1 
5518 40.5 ± 26.5 278.6 ± 44.2 
6101 791.4 ± 342.9 314.8 ± 139.8 
6114 76.2 ± 11.4 132.9 ± 27.1 
6208 120.1 ± 46.9 45.5 ± 20.3 
6304 21675.6 ± 3354.5 14497.9 ± 3316.4 
7102 3764.6 ± 416.2 2724.5 ± 740 
7701 883.7 ± 159.1 629.9 ± 94.3 
7807 513.3 ± --- 579.1 ± 39 
8016 73.1 ± 27.1 22.6 ± 7.3 
8111 127.8 ± 143.9 1002 ± 492.5 
9907 --- 911.9 ± 704 
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Table 21 Relative intensity of the spots differentially expressed in the cell line HT-29, detected by PDQuest 
software based on t-test at 95% confidence. Representation for each spot, considering the control group and 
treatment, the average relative intensity and respective standard deviation. 
SSP 
Control – 
(Mean ± SD) 
Compound 
(Mean ± SD) 
105 172.8 ± 104.4 625.8 ± 339.9 
202 322.7 ± 201 861.8 ± 227.6 
302 385.5 ± 185.6 722.5 ± 94.1 
1208 --- 296.6 ± 77.5 
2411 9511.3 ± 5830.3 28137.6 ± 8476.7 
2506 422 ± 213 1076.4 ± 306.9 
2605 647 ± 339 1460 ± 251.7 
2911 79.4 ± 35.06 184.2 ± 50.4 
3301 197 ± 129.3 --- 
4407 386 ± 140.2 1874.2 ± 1115.9 
4501 531.2 ± 75.3 --- 
5101 133.2 ± 63.7 289.6 ± 58.6 
5103 119.3 ± 72.2 346 ± 91.2 
5304 101.9 ± 80.9 304.7 ± 68.8 
5403 353.9 ± 161.4 635.8 ± 75.6 
5502 95.2 ± 38.4 79.8 ± --- 
5505 155.1 ± 58 301.7 ± 64.4 
5507 126.8 ± 59.5 453.5 ± 177.7 
5610 133.5 ± 83.5 480.1 ± 143 
5813 19.2 ± 10.8 153.9 ± 71.4 
6101 624.9 ± 294.6 1180 ± 354.5 
6103 --- 431.9 ± 54 
6201 213.5 ± 157.1 541.4 ± 118 
6412 186.8 ± 78.9 440.8 ± 184.2 
6502 192.1 ± 91.6 406.4 ± 123 
6809 158.5 ± 137.1 711.2 ± 260.3 
 
